0001140361-19-005168.txt : 20190319 0001140361-19-005168.hdr.sgml : 20190319 20190319070459 ACCESSION NUMBER: 0001140361-19-005168 CONFORMED SUBMISSION TYPE: 425 PUBLIC DOCUMENT COUNT: 108 FILED AS OF DATE: 20190319 DATE AS OF CHANGE: 20190319 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CELGENE CORP /DE/ CENTRAL INDEX KEY: 0000816284 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222711928 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34912 FILM NUMBER: 19690167 BUSINESS ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 BUSINESS PHONE: (908)673-9000 MAIL ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BRISTOL MYERS SQUIBB CO CENTRAL INDEX KEY: 0000014272 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 220790350 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 425 BUSINESS ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 BUSINESS PHONE: 2125464000 MAIL ADDRESS: STREET 1: 430 E. 29TH STREET STREET 2: 14 FLOOR CITY: NEW YORK STATE: NY ZIP: 10016 FORMER COMPANY: FORMER CONFORMED NAME: BRISTOL MYERS CO DATE OF NAME CHANGE: 19891012 425 1 s002621x38_425.htm 425
Filed by Bristol-Myers Squibb Company
Pursuant to Rule 425 of the Securities Act of 1933
and deemed filed pursuant to Rule 14a-6(b)
of the Securities Exchange Act of 1934
Form S-4 File No.: 333-229464
Subject Company: Celgene Corporation
SEC File No.: 001-34912


Explanatory Note: The following slides were used by Bristol-Myers Squibb Company at an investor presentation on March 19, 2019.


   Transaction Update  INVESTOR PRESENTATIONMARCH 19, 2019 
 
 Important Information For Investors And Stockholders This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectus equivalent document. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. In connection with the proposed transaction between Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) and Celgene Corporation (“Celgene”), on February 1, 2019, Bristol-Myers Squibb filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4, as amended on February 1, 2019 and February 20, 2019, containing a joint proxy statement of Bristol-Myers Squibb and Celgene that also constitutes a prospectus of Bristol-Myers Squibb. The registration statement was declared effective by the SEC on February 22, 2019, and Bristol-Myers Squibb and Celgene commenced mailing the definitive joint proxy statement/prospectus to stockholders of Bristol-Myers Squibb and Celgene on or about February 22, 2019. INVESTORS AND SECURITY HOLDERS OF Bristol-Myers Squibb and Celgene ARE URGED TO READ THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION.  Investors and security holders will be able to obtain free copies of the registration statement and the definitive joint proxy statement/prospectus and other documents filed with the SEC by Bristol-Myers Squibb or Celgene through the website maintained by the SEC at http://www.sec.gov.  Copies of the documents filed with the SEC by Bristol-Myers Squibb are available free of charge on Bristol-Myers Squibb’s internet website at http://www.bms.com under the tab, “Investors” and under the heading “Financial Reporting” and subheading “SEC Filings” or by contacting Bristol-Myers Squibb’s Investor Relations Department through https://www.bms.com/investors/investor-contacts.html.  Copies of the documents filed with the SEC by Celgene are available free of charge on Celgene’s internet website at http://www.celgene.com under the tab “Investors” and under the heading “Financial Information” and subheading “SEC Filings” or by contacting Celgene’s Investor Relations Department at ir@celgene.com.  Certain Information Regarding ParticipantsBristol-Myers Squibb, Celgene, and their respective directors and executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Bristol-Myers Squibb is set forth in its Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the SEC on February 25, 2019, its proxy statement for its 2018 annual meeting of stockholders, which was filed with the SEC on March 22, 2018, and its Current Report on Form 8-K, which was filed with the SEC on August 28, 2018. Information about the directors and executive officers of Celgene is set forth in its Annual Report on Form 10-K for the year ended December 31, 2018, which was filed with the SEC on February 26, 2019, as amended on March 1, 2019. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the definitive joint proxy statement/prospectus of Bristol-Myers Squibb and Celgene filed with the SEC and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. You may obtain these documents (when they become available) free of charge through the website maintained by the SEC at http://www.sec.gov and from Investor Relations at Bristol-Myers Squibb or Celgene as described above.  
 
 Cautionary Statement Regarding Forward-Looking StatementsThis communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. You can generally identify forward-looking statements by the use of forward-looking terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “explore,” “evaluate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” or “will,” or the negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond Bristol-Myers Squibb’s and Celgene’s control.Statements in this communication regarding Bristol-Myers Squibb, Celgene and the combined company that are forward-looking, including projections as to the anticipated benefits of the proposed transaction, the impact of the proposed transaction on Bristol-Myers Squibb’s and Celgene’s business and future financial and operating results, the amount and timing of synergies from the proposed transaction, the terms and scope of the expected financing for the proposed transaction, the aggregate amount of indebtedness of the combined company following the closing of the proposed transaction, expectations regarding cash flow generation, accretion to cash earnings per share, capital structure, debt repayment, and credit ratings following the closing of the proposed transaction, Bristol-Myers Squibb’s ability and intent to conduct a share repurchase program and declare future dividend payments, the combined company’s pipeline, intellectual property protection and R&D spend, the timing and probability of a payment pursuant to the contingent value right consideration, and the closing date for the proposed transaction, are based on management’s estimates, assumptions and projections, and are subject to significant uncertainties and other factors, many of which are beyond Bristol-Myers Squibb’s and Celgene’s control. These factors include, among other things, effects of the continuing implementation of governmental laws and regulations related to Medicare, Medicaid, Medicaid managed care organizations and entities under the Public Health Service 340B program, pharmaceutical rebates and reimbursement, market factors, competitive product development and approvals, pricing controls and pressures (including changes in rules and practices of managed care groups and institutional and governmental purchasers), economic conditions such as interest rate and currency exchange rate fluctuations, judicial decisions, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates, changes to wholesaler inventory levels, variability in data provided by third parties, changes in, and interpretation of, governmental regulations and legislation affecting domestic or foreign operations, including tax obligations, changes to business or tax planning strategies, difficulties and delays in product development, manufacturing or sales including any potential future recalls, patent positions and the ultimate outcome of any litigation matter. These factors also include the combined company’s ability to execute successfully its strategic plans, including its business development strategy, the expiration of patents or data protection on certain products, including assumptions about the combined company’s ability to retain patent exclusivity of certain products, the impact and result of governmental investigations, the combined company’s ability to obtain necessary regulatory approvals or obtaining these without delay, the risk that the combined company’s products prove to be commercially successful or that contractual milestones will be achieved. Similarly, there are uncertainties relating to a number of other important factors, including: results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies; the ability to enroll patients in planned clinical trials; unplanned cash requirements and expenditures; competitive factors; the ability to obtain, maintain and enforce patent and other intellectual property protection for any product candidates; the ability to maintain key collaborations; and general economic and market conditions. Additional information concerning these risks, uncertainties and assumptions can be found in Bristol-Myers Squibb’s and Celgene’s respective filings with the SEC, including the risk factors discussed in Bristol-Myers Squibb’s and Celgene’s most recent Annual Reports on Form 10-K, as updated by their Quarterly Reports on Form 10-Q and future filings with the SEC.It should also be noted that projected financial information for the combined businesses of Bristol-Myers Squibb and Celgene is based on management’s estimates, assumptions and projections and has not been prepared in conformance with the applicable accounting requirements of Regulation S-X relating to pro forma financial information, and the required pro forma adjustments have not been applied and are not reflected therein. None of this information should be considered in isolation from, or as a substitute for, the historical financial statements of Bristol-Myers Squibb or Celgene. Important risk factors could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to, the risks that: a condition to the closing of the proposed acquisition may not be satisfied; a regulatory approval that may be required for the proposed acquisition is delayed, is not obtained or is obtained subject to conditions that are not anticipated; Bristol-Myers Squibb is unable to achieve the synergies and value creation contemplated by the proposed acquisition; Bristol-Myers Squibb is unable to promptly and effectively integrate Celgene’s businesses; management’s time and attention is diverted on transaction related issues; disruption from the transaction makes it more difficult to maintain business, contractual and operational relationships; the credit ratings of the combined company decline following the proposed acquisition; legal proceedings are instituted against Bristol-Myers Squibb, Celgene or the combined company; Bristol-Myers Squibb, Celgene or the combined company is unable to retain key personnel; and the announcement or the consummation of the proposed acquisition has a negative effect on the market price of the capital stock of Bristol-Myers Squibb and Celgene or on Bristol-Myers Squibb’s and Celgene’s operating results. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do occur, what impact they will have on the results of operations, financial condition or cash flows of Bristol-Myers Squibb or Celgene. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on the proposed transaction and/or Bristol-Myers Squibb or Celgene, Bristol-Myers Squibb’s ability to successfully complete the proposed transaction and/or realize the expected benefits from the proposed transaction. You are cautioned not to rely on Bristol-Myers Squibb’s and Celgene’s forward-looking statements. These forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. You also should understand that it is not possible to predict or identify all such factors and that this list should not be considered a complete statement of all potential risks and uncertainties. Investors also should realize that if underlying assumptions prove inaccurate or if unknown risks or uncertainties materialize, actual results could vary materially from Bristol-Myers Squibb’s or Celgene’s projections. Except as otherwise required by law, neither Bristol-Myers Squibb nor Celgene is under any obligation, and each expressly disclaim any obligation, to update, alter, or otherwise revise any forward-looking statements included in this communication or elsewhere, whether written or oral, that may be made from time to time relating to any of the matters discussed in this communication, whether as a result of new information, future events or otherwise, as of any future date.This communication contains non-GAAP financial measures that are adjusted to exclude certain costs, expenses, gains and losses and other specified items that are evaluated on an individual basis. Non-GAAP information is intended to portray the results of our baseline performance, supplement or enhance management, analysts and investors overall understanding of our underlying financial performance and facilitate comparisons among current, past and future periods. This information is not intended to be considered in isolation or as a substitute for financial measures prepared in accordance with GAAP and may not be the same as or comparable to similarly titled measures presented by other companies due to possible differences in method and in the items being adjusted. 
 
 The Celgene Acquisition: A Financially and Strategically Compelling Transaction  >40%   ~10%   ~11%  $2.5Bn   Free cash flow in first three years  Credit rating provides future flexibility  Accretion to EPS in first full year (and accretive every year through 2025)  Accretive to DCF value per share  IRR, well above ~8% cost of capital  Run-rate cost synergies in year 3  >$45Bn   <1.5x   Debt/EBITDA by 2023  A3/A  Enhanced product leadership and pipeline #1 in oncology, #1 in cardiovascular, top 5 in immunology and inflammation9 current products over $1Bn in annual sales; 6 near-term product launches; robust early-stage pipeline Attractive valueApproximately $55 billion from marketed productsGreater than $20 billion from synergies Implies the Celgene pipeline was acquired for a highly attractive price when compared to the aggregate purchase price of $90 billionIdeal timing Trading ratio at 2-year lowsCelgene P/E near an all-time low when deal was announcedBought at low point in biotech stock market pricesSustainable financial strengthSales and earnings growth every year through 2025800bps accretive to operating margin even before synergies  1  Source: SEC filings 
 
 We Expect to Create Significant Value  More than 80% of transaction cost supported by value of currently marketed products and synergiesValue of currently marketed products reflects more conservative assumptions than Street analyst consensus, primarily driven by RevlimidStreet estimates for currently marketed products would imply value of ~$70Bn Implied cost of pipeline highly attractive given 5 late-stage pipeline assets (“Big 5”), >20 Phase 1/2 assets and leading cell therapy and protein homeostasis platforms  Celgene Components of Value  In $Bn    >80% of Transaction Cost  Source: SEC filings, Capital IQEquity purchase price plus net debtPrecedent takeover year 5 sales multiples – see page 8  Current biotech trading comp valuations – see page 33Median premium for biotech transaction >$2Bn 2018TD – see page 8  Other Pipeline Acquisition Benchmarks>$45Bn: Precedent biopharma acquisition multiples (9.8x2 median transaction multiple x ~$5Bn3 ’23E Street pipeline sales estimate)~$38Bn-$48Bn: Trading comps at standard biotech premiums (4-5x3 trading multiple x ~$5Bn ’23E Street pipeline sales estimate x 91%4 median premium)  $90Bn Transaction Cost  Implied cost to break-even  Significant value creation expected  1. The Celgene Acquisition: A Financially and Strategically Compelling Transaction 
 
 Analysis, Including DCF, Based on Conservative, Risk-Adjusted Projections for Celgene  Source: Capital IQ, SEC filingsCapital IQ median as of 01/02/2019    Consensus1    Celgene Blended Mgmt. Case    BMS Projections for Celgene  Conducted extensive due diligence on Revlimid IP estateModeled base commercial assumptions more conservatively than both Street consensus and Celgene management projections, primarily driven by RevlimidEvaluated range of scenarios including early-at-risk launch, which remains low probabilityTransaction creates value to BMS shareholders across all scenarios evaluatedEstimates include pipeline contribution on risk adjusted basis  2019E – 2023E Celgene Projected Revenue – Conservative BMS Projections Relative to the Street and Celgene’s Forecast  Revenue, $Bn  1. The Celgene Acquisition: A Financially and Strategically Compelling Transaction 
 
 Positive Revlimid Patent Decisions Post-Announcement Further De-Risk Our Forecast  Recent US Patent and Trademark Office (USPTO) decisions declining to institute inter partes reviews (IPRs) challenges on Revlimid patents further de-risks our Revlimid forecastOn February 11, 2019, the USPTO denied requests by Dr. Reddy’s Laboratories to institute inter partes reviews of Celgene’s 3 Revlimid MDS patentsOn March 14, 2019, the USPTO denied petition by Alvogen to institute inter partes reviews of Celgene’s Revlimid patents related to dosing for multiple myeloma  1. The Celgene Acquisition: A Financially and Strategically Compelling Transaction  “This morning, Alvogen's IPR filing against CELG's 7,968,569 patent covering Revlimid's dosing for MM (the last of these IPRs) was just rejected by PTAB, as we had expected - essentially securing the 2023 backstop for Revlimid exclusivity…”“We continue to see a broad settlement between CELG and generic manufacturers as the most likely outcome…”“…we now believe a surprise early introduction of multiple Revlimid generics is unlikely until after the 2023 multiple myeloma patents expire.”“While this same patent is being tried in an ongoing litigation case, the IPR dismissal does remove one scenario in which unencumbered generic Revlimid could enter the market earlier than expected.”  Key Recent Decisions  Selected Research Analyst Commentary    March 14th  March 14th  March 14th  1  2 
 
 Celgene Provides a ‘String-of-Pearls’ in One Transaction and at an Attractive Valuation  Traditional ‘string-of-pearls’ strategy difficult, longer to execute and requires significant premiumsRequires successfully identifying and winning multiple potentially competitive processesStreet estimates for Celgene pipeline revenue in FY5 (2023) of approximately $5Bn  Public Biopharma Acquisitions from 2018 to Current(Enterprise Value $2Bn-$20Bn)  Source: Capital IQ, SEC filings  Implied Enterprise Value / Fiscal Year 5 Revenue Multiple  Premium to Unaffected  1. The Celgene Acquisition: A Financially and Strategically Compelling Transaction 
 
 Near-Term Performance Relatively De-Risked  Combined company growth to be driven by existing key market-leading franchisesConservative BMS forecast for Celgene below Street consensus and Celgene management projectionsCelgene’s “Big 5” near-term launches significantly de-risked Combined portfolio of >40 Phase 1 & 2 programs with potential to launch in the 2023+ timeframe  2019E – 2023E BMS Revenue Projections for Combined Company 1  $Bn  Source: SEC FilingsBMS Projections for Bristol-Myers and Celgene  Celgene Pipeline as % of BMS + Celgene Revenue   Celgene Revenue   Bristol-Myers Squibb Revenue  luspatercept   liso-cel (JCAR017)  bb2121  fedratinib  ozanimod  Phase 3 / Pivotal Complete        ~0%  ~0-5%  <5%  <10%  ~10-15%  US Submission 2H:19  Potential Approval 2H:20  1. The Celgene Acquisition: A Financially and Strategically Compelling Transaction 
 
 The Acquired Portfolio Strengthens Our Strategic Position  Bolsters Leading Franchises and Pipeline  #1 in oncology; #1 in cardiovascular; Top 5 in immunology and inflammationPremier commercial hematology business9 current products > $1Bn in annual salesAdds “Big 5” pipeline of first-in-class or best-in-class assetsAdds robust early-stage pipeline with Phase 1 / 2 programs to support next wave of launches  Creates Stronger Company   Sales and earnings increase every year through 2025Meaningfully enhanced margin profile – standalone operating margin of 28% to pro forma margin of 36% / 43% (excluding / including synergies)Strong balance sheet enabling pursuit of future innovation   Enhances Diversification   More diversified and younger portfolio with 6 combined potential product launches in next 24 monthsSignificantly reduced concentration of top 3 existing products in 2025 (from ~70% of sales on standalone basis to ~45% of sales on combined basis)Combined company better positioned to address eventual loss-of-exclusivities of Opdivo and Eliquis  1. The Celgene Acquisition: A Financially and Strategically Compelling Transaction 
 
 Opportunistic Timing Resulted in Attractive Purchase Price  And Our Offer Price Was Lower Than Analyst Price Targets for Celgene  6.7x  Celgene NTM P/E 1  Source: Capital IQConsensus estimate; not burdened by stock-based compensationExcludes CVR valueDefined as Celgene stock price divided by Bristol-Myers stock priceTransaction was withdrawnBased on final publicly announced offer  17.1x  9.9x  Implied P/E based on 1/2/2019 Offer Price2  AnnounceDate  Acquiror  Target  NTM P/E  5/8/2018  Takeda  Shire  12.8x  1/11/2016  Shire  Baxalta  21.3x  11/23/20154  Pfizer  Allergan  27.2x  11/17/2014  Actavis  Allergan  27.5x  7/18/20144  AbbVie  Shire  26.0x  5/18/20144, 5  Pfizer  AstraZeneca  21.6x  3/9/2009  Merck  Schering-Plough  14.0x  1/26/2009  Pfizer  Wyeth  13.7x  4/26/2004  Sanofi  Aventis  19.0x     Median    21.3x  1/3/2019  Bristol-Myers  Celgene  9.9x    Better / (Worse) Median    11.4x    Better / (Worse) Cheapest Precedent    2.9x  $67  Celgene Stock Price  Offer Price as of 1/2/19  Celgene Price Target  $94  $112  $105  $102.42  Celgene’s NTM P/E Multiple Had Been Declining…  Our Acquisition Multiple Is Significantly Better Than Precedent Transactions   The Trading Ratio3 of BMS / Celgene Was At Two-Year Lows…  Opportunistic timing given favorable relative valuation of BMS versus Celgene equity  Source: Capital IQ, SEC FilingsDefined as Celgene stock price divided by Bristol-Myers stock pricePer Bristol-Myers Financial Advisors, as disclosed in S-4. Midpoint DCF value  1.3x  1.8x  2-year Average  We Are Buying Great Assets At The Right Moment    1. The Celgene Acquisition: A Financially and Strategically Compelling Transaction 
 
 Analysts Have Endorsed Both The Strategy and The Value  “Beyond the lack of alternatives that could provide a similar level of upside to the proposed deal (we note that the opposing shareholders have not come forward with any sort of concrete Plan B, with no over-the-top bidders in sight), we think the financial terms of the deal are very favorable and we’d characterize the Celgene pipeline as quite strong and fairly de-risked already.”  March 6th  “BMY’s combined confidential and internal review appears sufficiently robust…”  March 6th  “We agree with the value of the cost synergies, and believe the pipeline valuation is reasonable, if not favorable to Bristol in light of other Biopharma deals. Our conversations with investors suggest growing support for the CELG merger, particularly given management's rational argument about positioning for after 2025 given upcoming LOEs.”  Feb 14th   “Investors are likely to see greater strategic appeal for the CELG deal, which brings revenue diversification, pipeline opportunities and meaningful synergies.”  Jan 25th  “We also applaud management for making such a bold strategic move, as we think the step-up in the organic R&D budget and cash flow should improve the enlarged group’s ability to mitigate medium-term patent expiries and thus deliver upside surprise, whilst simultaneously growing the dividend.”  Jan 15th  “The CELG acquisition adds strategic assets in oncology, hematology, and immunology / inflammation that creates a more balanced portfolio.”  Jan 3rd  “We believe the deal makes strategic sense with complementary franchises in Oncology and Immunology & Inflammation (I&I)...”  Jan 3rd  “The combined entity will likely emerge as one of the largest oncology companies, highlighted by mega-blockbuster drugs such as Revlimid, Pomalyst, Opdivo, and Yervoy; in addition, the merger enables the pooling of resources to build a growing immunology and inflammation (I&I) franchise.”  Jan 3rd  “…combination is highly accretive in the near and medium term based on our P&L and cost-synergy assumptions…”   Jan 3rd  “In our view Bristol paid a fair price for Celgene and we think that Celgene is poised to undergo a significant re-rating in 2019. In fact, we highlighted Celgene as one of our favorite names in the space in our 2019 Outlook this morning.”  Jan 3rd  1. The Celgene Acquisition: A Financially and Strategically Compelling Transaction  “CELG still looks like the best option to us. We think a big part of the opposition to the BMY/CELG deal comes from the idea that there is a better option for Bristol-Myers Squibb shareholders waiting around the corner. We think this presents a false hope for investors...”  March 12th 
 
 Strong operating performance drives long-term value creationWhile we are not satisfied with recent share price performance, largely driven by dynamics in first-line lung cancer, the BMS team has generated a track-record of strong operating and financial results: 5-year CAGRs for net revenue and adjusted EPS of 7% and 17%, respectively, both in excess of peer median Improved adjusted operating margin by 725 basis points over that time periodConsistently met or exceeded top line and EPS guidance and estimates on an annual basis each year since 2013Industry-leading commercializationOpdivo, the most successful commercial oncology launch ever, has a leadership position in 16 FDA approved indications and has delivered $6.7Bn in 2018 sales, up 36% year-over-yearEliquis is the #1 world-wide novel anti-coagulant despite being the 3rd entrant to market; it has generated $6.4Bn in 2018 sales, 32% growth year-over-yearPortfolio transition successTransitioned portfolio through multiple Losses of Exclusivity (LOEs) over the last 5 years Approximately ~60% of 2018 sales coming from new products launched during that period  We Have A Record of Financial and Operational Outperformance  2 
 
   Net Sales, $Bn  We Have a Strong Track Record of Financial Results…  $16.4  $15.9  $16.6  $19.4  $20.8  $22.6  CAGR6.6%  Adj. Operating Income1, $Bn  CAGR13.1%  Adj. Operating Margin1 %  Adj. EPS  +725bps  21.1%  21.8%  23.4%  25.9%  25.0%  28.3%  $3.5  $3.5  $3.9  $5.0  $5.2  $6.4  $1.82  $1.85  $2.01  $2.83  $3.01  $3.98  CAGR16.9%  Source: Company FilingsDefined as non-GAAP gross profit less SG&A and R&D expenses  2. We Have A Record of Financial and Operational Outperformance 
 
 …With a High Degree of Execution Consistency  Adjusted EPS Results Have Beat or Met Consensus Expectations in 92% of Quarters Since the Beginning of 2013 (22/24 Quarters)1  Quarterly EPS ($ / share); 1Q 2013 – 4Q 2018                                                  Sales Have Beat or Met Consensus Expectations in 88% of Quarters Since the Beginning of 2013 (21/24 Quarters)1  Quarterly Sales ($Bn); 1Q 2013 – 4Q 2018                                                  Actual vs Consensus:  BMS has met or exceeded annual top-line and EPS guidance & estimates each of the past 5 years  Actual vs Consensus:  Beat/Meet1:  Beat/Meet1:  Source: Thomson, Company FilingsBeat/Meet in a given quarter defined as actual results greater than or equal to Thomson consensus median estimates  2. We Have A Record of Financial and Operational Outperformance 
 
   Opdivo’s Commercial Success Demonstrates Our Ability to Maximize the Value of Our Pipeline  Top Oncology Products: Cumulative Sales in 4 Years Post Launch  US Sales ($Bn)  Approvals Post-Launch              0  2  4  6  8  10  Opdivo  Avastin  Taxotere  12      14  16  in Yearsin the U.S.  Approvals   16  4  Source: IQVIA NSP $ Sales US only  2. We Have A Record of Financial and Operational Outperformance 
 
   BMS Share Price Since Opdivo Initial FDA Approval in Melanoma  Share Price Volatility Driven By 1L Lung, Despite Strong Operating Performance and Success of Opdivo Franchise  Share Price ($)  Source: Thomson, Company Filings, Capital IQ  Prior to August 5, 2016, we outperformed peers over 1-, 3-, and 5-year periodsStock price performance since then has been disproportionately driven by clinical trial results in lung cancer, including Opdivo and competitors  October 19, 2018: FDA extends review timeline for Opdivo in 1L NSCLC with TMB  April 16, 2018: Merck presents strong KEYNOTE-189 data at AACR annual meeting  August 5, 2016 / October 9, 2016: CheckMate-026 trial failed to meet primary endpoint; Presents results at ESMO  January 19, 2017: Will not pursue an accelerated regulatory pathway for combo Opdivo + Yervoy in first-line lung in the U.S.  Consistent Track Record of Outperforming Analyst Estimates for Opdivo Franchise  Quarterly Sales ($Bn); 4Q 2014 – 4Q 2018  Actual vs Consensus:  Beat/Meet3:                                    (10%)  +36%  +20%  +12%  +18%  +2%  (1%)  +11%  +17%  +4%  +5%  +5%  +9%  +5%  +6%  (1%)  0%  2. We Have A Record of Financial and Operational Outperformance  Total Shareholder Return Leading up to CheckMate-026 (As of August 4, 2016)  Peer group for Bristol-Myers based on S-4 peersAs of December 22, 2014 (first approval in US)Beat/Meet in a given quarter defined as actual results greater than or equal to Thomson consensus median estimates 
 
 Opdivo’s Future Growth Potential is Driven By:Broadened first line lung cancer programMultiple registered trials in various tumor typesIndustry leading development program in the adjuvant setting  Lung  2L Leadership with 28% BMS I-O share3L+ SCLC Leadership with 68% BMS I-O share  Melanoma  1L Leadership with 60% BMS I-O shareAdjuvant Leadership with 77% BMS I-O share  Renal cell Carcinoma  1L Leadership with 44% BMS I-O share2L Leadership with 52% BMS I-O share  Head & Neck  Post platinum 18% BMS I-O share  2L Hepatocellular Carcinoma  2L Leadership with 57% BMS I-O share  Despite Competitive Intensity, BMS Continues to Lead in Key Tumors Where Opdivo is Approved  … BMS Has Maintained I-O Leadership Across Many Key Tumors  BMS I-O share includes Opdivo and Yervoy share in combination and/or monotherapy  BMS Share Source: AIRxShare Jan-19 (8WRA for NSCLC, 13WRA for all other tumors); SCLC 3L+ share is for the month of Dec-18. CRC, HL, Bladder and stage III unresectable NSCLC shares are not available to BMS; Overlapping approvals with Opdivo (total 16 indications across 9 tumors): Keytruda approvals in: Adjuvant and Metastatic Melanoma, 2L Lung, PP H&N, 2L HCC. Tecentric approvals in: 2L Lung  2. We Have A Record of Financial and Operational Outperformance  U.S. Approval  Commercialization  Product  Sep. 2014      Dec. 2014      May. 2016      Mar. 2017      May. 2017      Sep. 2018      While Competition Has Been Substantial… 
 
     Our R&D Productivity is Strong  P31: add point on new head/talent and capabilities in translational medicine as pipeline evolves  Non-GAAP R&D spend per US Approval of a new molecular entity or new indication for an already approved product | Sources include Company Financial Reports, Drugs@FDA and BIA R&D AnalysisIndustry benchmarking by KMR Group | 2017 was the latest year for which data are currently available  Phase 3 program starts  Major market approvals  Phase 3 success  Portfolio-Wide Progress  ONCOLOGY  25+ registrational trials in 15 tumor types reading out in next 4 yearsIndustry-leading position in adjuvant setting, the largest opportunity for checkpoint inhibitors  IMMUNOSCIENCE  Developed the leading TYK-2 inhibitors, a highly promising and sought-after targetOngoing Phase 3 in psoriasis; Phase 2/3 trials across 6 indications planned  CARDIOVASCULAR  Leading with the innovative Factor XIa program with potential to improve safety and efficacy of existing novel anticoagulants ($15Bn in 2018 sales)  BMS Leading Efficiency in R&D Spend (Per U.S. Approval)1(2015 – 2018; $Bn)  Late-Stage Oncology Performance2(2015 – 2017)  Peer set includes top 15 R&D spend  2. We Have A Record of Financial and Operational Outperformance 
 
 Products sourced through acquisitionof for ~$2Bn1     $6.7Bn     $1.3Bn    $2.7Bn     $2.0Bn   We Have Successfully Developed Our PortfolioThrough Both Internal Investment and Acquisitions  The Celgene acquisition continues our balanced approach to delivering new medicines    INTERNAL    EXTERNAL  2018 Sales:  2018 Sales:    $6.4Bn   2018 Sales:  Acquired from DuPont in 2001 as a preclinical compound; developed at BMS and partnered with Pfizer  Internally Developed  2. We Have A Record of Financial and Operational Outperformance  $2.1Bn fully diluted purchase price at time of announcement, net of acquired cash and equivalents; purchase price on non-diluted basis equates to ~$1.8Bn 
 
 Comprehensive process Prioritized more than 20 transformational and ‘string-of-pearls’ opportunitiesCelgene selected as most attractive opportunityThorough Board oversight Consistent Board involvement throughout process8 meetings to discuss Celgene opportunity, in addition to review by the Board’s Science and Technology CommitteeExtensive diligence 6-month deep-dive analysis provided comprehensive view of Celgene’s opportunities and risks5 subsequent weeks of confidential due diligence confirmed strength of the opportunityDiligence included drug development and clinical specialists, health authority experts, drug development and metabolism experts, IP litigators, finance, HR and technology leads, together with organizational leaders and supported by third party expertsFocused and committed to a successful integration Complementary businessesRigorous planning process for integrationStrong team absolutely aligned to execute on the integration  Our Robust Process Was Characterized By Strong Oversight, Extensive Diligence and Focused Planning  3 
 
    7 companies prioritized for deep dive analysis based on additional financial and strategic criteriaIncluded both transformational and 'string-of-pearls'  77 biopharma opportunities identified;22 prioritized for assessment based on strategic fit  Celgene identified as lead opportunity based on strategic and financial criteriaContinued assessment of ‘string-of-pearls’ opportunities as an alternative  A Robust Strategic Review Led Us To This Transaction  Acquiring Celgene’s Big-5 late-stage pipeline, plus its >20 Phase 1 and 2 clinical programs, presented a greater value creation opportunity than other strategic alternatives given:the scarcity of attractive biotech opportunities, high premiums paid in bolt-on acquisitions, a longer timeline for a series of acquisitions and the additional risk we might not prevail in every competitive auction  Continued deep fundamental assessment of Celgene based on public information  Identified 6 franchise options, but determined each would have only limited strategic and/or financial impact  Early / Mid-2018  June 2018  Sept 2018  Oct/Nov2018  Nov/Dec2018  Jan2019  Followed by rigorous confidential due diligence process  BoD approval and announcement  Alternatives Considered  Considered 'string-of-pearls' and transformational strategic M&A opportunities  Parallel assessment of asset swaps and joint ventures with peer companies        The Board held 8 meetings between June 2018 and January 2019 to discuss the merits of the Celgene opportunity  3. Robust Process, Extensive Diligence, and Focused Integration Planning 
 
 We Considered Other Alternatives;Celgene Was By Far the Best Value Creation Opportunity  ‘String-of-Pearls’ Acquisitions    Value: Requires more significant premiumsMedian premium was 91% for $2-20Bn deals in the sector since 2018Timing: Would take longer to executeRisk: Requires winning multiple potentially competitive processes  Substantial Share Repurchase     Value: Share repurchase of $15Bn funded with a mix of cash and debt, resulting in same estimated credit rating as the Celgene acquisition, would yield year one accretion of only ~16% vs. >40% for Celgene acquisitionLimited Benefit: No synergies, strategic benefits or diversification and does not enhance long-term growth  Other Transformative Transactions    Celgene was the most financially and strategically compelling opportunity available  Alternative Considered  Reasons for Rejection  3. Robust Process, Extensive Diligence, and Focused Integration Planning 
 
 We Mitigated Potential Risks At Multiple Points  We Involved an Experienced Board at All Stages of the ProcessBoard consistently involved throughout strategic process; 8 meetings to discuss Celgene opportunity aloneBoard Integration Committee will oversee all aspects of merger integrationWe Used Conservative Projections to Model the Acquisition Analysis based on conservative, risk adjusted projections for Celgene, using more conservative projections for RevlimidOur model was below both Street consensus and Celgene management projections in near-term, primarily driven by RevlimidWe Identified Actionable Cost Synergies and Rigorously Planned Integration$2.5Bn of specific, actionable run-rate cost synergies, and a plan to achieve them by the third full yearIntegration strategy reinforced by compensation changes to drive successful executionWe Negotiated a Better Deal for ShareholdersNegotiated a price reductionUtilized a Contingent Value Right (CVR)We Leveraged Ideal Timing To Improve ValueAnnounced acquisition near an all-time low Celgene P/EIdeal timing with XBI biotech index having recovered 26% 2019 YTD  3. Robust Process, Extensive Diligence, and Focused Integration Planning 
 
 Our Robust Post-NDA Diligence Process Was Consistent With Precedent Transactions  NDA Signed  IP Diligence Begins  Management Presentation  11/23/18  41 days prior to announcement  11/28/18  36 days prior to announcement  12/13/18  21 days prior to announcement    All Completed Acquisitions of Public Biopharma Companies Over $40B in the Last 10 Years  +  +  Source: Company filings  4/22/18: NDA signed (16 days prior to announcement)4/24/18: Shire issues press release stating it has agreed to engage in discussions / due diligence based on revised Takeda offer5/8/18: Announcement date  1/15/09: NDA signed (53 days prior to announcement)2/22/09: In the days that followed, companies began due diligence3/9/09: Announcement date  1/16/09: NDA signed / due diligence initiated1/26/09: Announcement date    +  +  +  11/5/14: NDA signed / due diligence initiated11/17/14: Announcement date  14 days of post-NDA diligence  12 days of post-NDA diligence  15 days of post-NDA diligence  10 days of post-NDA diligence  3. Robust Process, Extensive Diligence, and Focused Integration Planning 
 
 The Transaction Was Overseen By An Experienced Board Of Directors Which Has Delivered Significant Value  Experienced, Fit-for-Purpose Board  Independent, refreshed and effective10 / 11 directors independent (91%)Strong Lead Independent Director with robust responsibilities and oversightAdded 5 new directors in the last 3 years, combining fresh perspectives with deep institutional knowledgeAverage tenure of 5.5 years vs. S&P 500 average tenure of 9.0 yearsStrong track records of shareholder value creationAggregated over their C-Level and board tenures, our directors helped deliver TSR which outperformed the S&P 500 by 38% and the DRG NYSE Arca Pharmaceutical Index by 54%Significant Experience in M&A Involved in 4 M&A deals valued over ~$20Bn as C-Level executives or directors>$170Bn of deals over $5Bn by BMS directors  Healthcare  Public CompanyCEO/CFO  Financial  Risk Management  Sales & Marketing  International  Science / Technology/ Innovation  Director Skills and Experience  3. Robust Process, Extensive Diligence, and Focused Integration Planning 
 
 Our Revised Compensation Program To Drive Successful Execution and Value Creation  Short-Term  Annual incentive plan will include assessment of key integration execution metrics:Near-term pipeline delivery milestonesHuman capital managementSynergy savingsIntegration metrics will be a core component of 2020 Annual Bonus Plan for entire Leadership Team  Outstanding PSU awards will include indicators of post-merger progress:Multi-year progress against key integration execution metricsCombined company revenue goals, andRelative TSRPSU awards in 2020 will include financial and operational metrics that support merger and integration success    Financial, Operational and R&D Performance    Post-Merger Integration Metrics (inclusive of pipeline)    Stock Price Performance (reflective of pipeline)  78% of outstanding awards based on overall integration efforts  Pre-Close  Post-Close  3. Robust Process, Extensive Diligence, and Focused Integration Planning  Long-Term  Key Integration Metrics Built into Executive Compensation Program  Alignment of Incentives 
 
 A Financially and Strategically Compelling Transaction  >40%   ~10%   ~11%  $2.5Bn   Free cash flow in first three years  Credit rating provides future flexibility  Accretion to EPS in first full year (and accretive every year through 2025)  Accretive to DCF per share  IRR, well above ~8% Cost of Capital  Run-rate cost synergies in year 3  >$45Bn   <1.5x   Debt/EBITDA by 2023  A3/A  Enhanced product leadership and pipeline #1 in oncology, #1 in cardiovascular, top 5 in immunology and inflammation9 current products over $1Bn in annual sales; 6 near-term product launches; robust early-stage pipeline Attractive valueApproximately $55 billion from marketed productsGreater than $20 billion from synergies Implies the Celgene pipeline was acquired for a highly attractive price when compared to the aggregate purchase price of $90 billionIdeal timing Trading ratio at 2-year lowsCelgene P/E near an all-time low when deal was announcedBought at low point in biotech stock market pricesFinancially strong combined companySales and earnings growth every year through 2025800bps accretive to operating margin even before synergies  Vote the White Proxy Card FOR ... a Company Better Positioned to Deliver Value  Source: SEC filings 
 
   Appendices:  Appendix A: Supporting InformationAppendix B: The “Big 5” OpportunityAppendix C: Our March 6, 2019 Investor Presentation 
 
   Appendix ASupporting Information 
 
 October 8, 2018: Positive Phase 3 STYLE study of Otezla in scalp psoriasisOctober 23, 2018: Positive results from Revlimid study in smoldering multiple myeloma October 25, 2018: Strong 3Q18 earnings; including a beat on revenue and EPSDecember 1/2, 2018: Positive luspatercept Phase 3 results at the ASH conference  Opportunistic Timing for Celgene Acquisition   Source: Capital IQ, Company Filings  Price Performance August 31, 2018 to March 14, 2019  As of 1/2/19: $67  91  Celgene$94  Celgene’s stock price tracked the decline of the XBI biotech index from Labor Day to deal announcement, despite mostly positive clinical newsflowCelgene declined (29%) versus the XBI index performance of (27%) over the same periodBiotech stocks have rebounded in 2019, with the XBI biotech index up +26% year-to-date  XBI100  XBI Index Up +26% 2019TD  Celgene down (29%) from Labor Day to Announcement  A  B  C  D  A  B  C  D  Positive Readouts Pre-Announcement:  Celgene Stock Tracked Biotech Decline Despite Mostly Positive Clinical Newsflow  
 
 Comparable Large Acquisitions Have Created Long-Term Value  Initial share price reactions are not indicative of long-term performanceMore near-term blockbuster products than prior large pharma transactionsLowest P/E multiple paid in large pharma transactions  Terms        Announcement Date  January 3, 2019  March 9, 2009  January 26, 2009  Enterprise Value ($Bn)  $90  $46  $65  Pro Forma Target Ownership  31%  32%  16%  NTM P/E  9.9x  14.0x  13.7x  % of Revenue from Target (1)        1 Year Post-Acquisition   43%  45%  32%  3 Years Post-Acquisition   41%  47%  37%  Key Statistics        >$1Bn Products from Target (5 Years Post Acquisition) (2)  6  4  3  Acquiror Price Performance (3)  Absolute / Vs. Peers  Absolute / Vs. Peers  Absolute / Vs. Peers  1-Day  (14%) / (14%)  (8%) / (9%)  (10%) / (11%)  1-Month  (5%) / (7%)  +17% / +8%  (24%) / (15%)  Through Close  N/A  +35% / +10%  +1% / (3%)  Post-Close To Current  N/A  +258% / +91%  +136% / +21%  Source: Capital IQ, Thomson, SEC Filings, Evaluate PharmaBased on BMS Projections for Combined Company for BMS / CELG; based on Thomson estimates for Merck & Pfizer transactionsNumbers for Merck’s acquisition of Schering-Plough and Pfizer’s acquisition of Wyeth are based on actual 2014 results and includes products from cardio JV in Merck total; figures for Bristol-Myers’ acquisition of Celgene based on Evaluate Pharma 2024 estimates    Peer group for Bristol-Myers based on S-4 peers; peers for Pfizer and Merck includes AZN, BMY, GSK, JNJ, LLY, MRK, NOVN, PFE, ROG, SAN; Bristol-Myers, Merck and Pfizer excluded from calculation for their own relative performance; current data as of 3/14/2019 
 
   Acquiring a Pipeline Comparable to Celgene’s at the Price We Are Paying Would Be Unachievable via Public Biotech Targets  Based on focused on biopharma entities with main equity listing in US; excludes companies with >$50Bn aggregate valueMarket data as of 3/14/2019; enterprise values based on Capital IQSales data based on Evaluate PharmaCelgene statistics exclude currently marketed products; ~$5Bn of 2023E revenue for Celgene based on Wall Street estimates   Products >$200MM 2023E Revenue3  Enterprise Value ($Bn)2  Company  EV / 2023E Revenue3  Phase 1/2 Assets   2023E Revenue ($Bn)3    Pipeline 4      Selected Comparables Include Biopharma Companies with >$2Bn in Sales in 20231  Rare combination of five sizable near-term launches and a broad portfolio of 20+ early-stage assets would be exceptionally challenging and costly to reproduce from available public comparables 
 
   Tom Lynch (preeminent lung cancer expert and former Chairman/CEO of Massachusetts General Physicians Organization) to enhance our R&D leadershipSaurabh Saha (ex-Delinia CEO, ex-Atlas Venture partner) to strengthen our Translational Medicine capabilitiesKate Owen (clinical trial expert at Novo Nordisk and Covance) to ensure industry-leading clinical trial executionEmma Lees (former SVP, Jounce Tx) to establish R&D hub in Cambridge focused on I-O resistance  Actions Taken Post CheckMate-026 Further Strengthen Our R&D Capabilities  Prioritized Translational Medicine to increase focus on tumor biology, data and analytics, and IO resistanceBroadened combinations with non-IO mechanisms, including chemotherapy and TKI combos (e.g., CheckMate-9ER)Increased focus on patient segmentation and diagnosticsEstablished a leading position in developing Opdivo for adjuvant indications1  Oncology Strategy  Expertise and Capabilities  Recruited a number of catalyst hires including:  Credit Suisse analysis and estimates 
 
   BMS Clinical Trial Outlook  31 ONGOING REGISTRATIONAL PROGRAMS   34 REGIS. & PoC TRIALS PLANNED in 20191  30+ KEY DATA READOUTS (2019 – 2023)1  REGISTRATIONAL ONCOLOGY TRIALS  EARLY ONCOLOGY PIPELINE  INNOVATIVE MEDICINES  25+ trials in 15 tumor types reading out 2019 – 2023 (20+ trials in 10 priority tumors)7 ongoing adjuvant trials; start reading out in 2020  Randomized Ph2 trials ongoing across 4 to 5 programsData expected in 2019 to enable decisions on reg. studies    TYK2 in Ph3 psoriasis; opportunity to broaden based on Ph2 readouts FXIa program (w/Janssen) starting Ph2 in secondary strokeFGF21 Ph2b trials ongoing to enable Ph3 program  Non-risk adjusted 
 
 P31: add point on new head/talent and capabilities in translational medicine as pipeline evolves  Trial  Expected Timing  Rationale  CM-227(Part 1a)  1H 2019  Opdivo + Yervoy or Opdivo monotherapy vs. chemotherapyTests hypothesis that IO can bring benefit to patients and eliminate chemotherapy as a standard of care  CM-227(Part 2)  Mid 2019  Opdivo + chemotherapy versus chemo aloneBuilds case for Opdivo + chemotherapy use in an approach validated by other studies  CM-9LA   2020  Opdivo + Yervoy + only 2 cycles of chemotherapy, versus standard chemo aloneTests hypothesis that Opdivo + Yervoy can enhance survival, while 2 cycles of chemotherapy limits rapid disease progression and mitigates side effects associated with a full course of chemo  Comprehensive Program Targeting First-Line Lung Cancer 
 
 During CEO’s Tenure, Our Compensation Program Has Evolved to Support Our Biopharma Strategy and Align With Shareholders  Historical Program Design  2016 Program Enhancements  Metrics: EPS (50%), Revenue (25%) and Pipeline (25%)Individual Performance Factor: Rewards results and behaviorsMax bonus payout: 251% of target  Enhanced disclosure around individual performance factors considered Reduced max bonus payout to 200% of target  PSU Metrics: EPS (70%) and Revenue (30%) measured over 1 year with a 3-year relative TSR modifier (+/-20%)MSUs: 4 tranches of shares earned based on 1-,2-,3- and 4-year stock price performance  Established 3-year performance measurement for all metricsRebalanced PSU measures with a heavier weighting on TSR (34%)Replaced EPS with Operating Margin (weighted 33%)  Market median pay philosophySignificant stock ownership guideline requirementsRequirement to hold 75% of net shares for 1 year  Significant Emphasis on Long-Term Compensation  Bonus Plan  LTI Plan  90% performance-based compensation    Note: Dr. Caforio became CEO on May 5, 2015; in our incentive plans, our metrics are defined as follows: Total Revenues (ex-fx), non-GAAP diluted EPS and non-GAAP Operating Margin 
 
   Appendix BThe “Big 5” Opportunity 
 
 Why Are the Big 5 Such a Powerful Opportunity?  Innovative ProgramsAll 5 are First-in-Class or potentially Best-in-ClassNear Term ApprovalsExpected launches in 2019 and 2020De-risked Assets3 out of the Big 5 have completed Phase 3 / pivotal trials2 have been submitted for regulatory approvalCVR will be paid only if all 3 selected assets are approvedLarge & Diversified OpportunityBig 5 and TYK2 have >$15Bn in non-risk-adjusted revenue potentialIncreases diversification of portfolio offering in Oncology, and Immunology and InflammationBMS Track Record of Success, and Value Added CapabilitiesSuccessfully transitioned mature portfolio into new growth assets derived from both internal and external sourcesDeep commercial knowledge and existing infrastructure in the Big 5 Therapeutic classes 
 
 Five Near-Term Product Launch Opportunities  luspatercept   liso-cel (JCAR017)  bb2121  fedratinib  ozanimod  Description  CVR  Near-Term Milestones / De-Risking Events        Best-in-Class selective S1P in relapsing forms of MS and First-in-Class in Inflammatory Bowel Disease  First- and Best-in-Class novel anemia drug  Potentially Best-in-Class cell-therapy for a form of non-Hodgkin (DLBCL)  First-in-class cell-therapy for Multiple Myeloma  Potential to be the first & only medicine for Myelofibrosis patients resistant/refractory to Jakafi  1Q19: U.S. NDA and EU MAA submissions for RMS planned  1H19: U.S. and EU regulatory submissions in 2L MDS and Beta-Thalassemia  2H19: U.S. submission expected  Currently in pivotal trials2H20: Potential U.S. approval  U.S. submission accepted with Priority Review by FDA 2H19: Potential U.S. approval 
 
   Convenient oral option to treat patients with Multiple Sclerosis (MS) in a ~$23Bn segmentStrong efficacy profile and differentiated safety profile shown in two positive pivotal trialsRelapsing-Remitting Multiple Sclerosis (RRMS) filed in EU and on track to refile in U.S. 1Q 2019First-in-Class in Inflammatory Bowel Disease (IBD) launching into a ~$17Bn segmentUlcerative Colitis reading out mid-2020 & Crohn’s Phase 3 underway  Ozanimod Overview 
 
   Source: FDA labels, clinicaltrials.gov Note: Cross Trial ComparisonAvonex ARR from Ozanimod Phase 3 clinical trial, Rebif ARR from Ocrevus Phase 3 clinical trialAnnualized relapse rate (ARR)      Oral  IV    Subcutaneous / intramuscular1  Strong Efficacy Profile and Potentially Best-in-Class Safety Profile Demonstrated in Two Positive Phase 3 Trials  Efficacy in RRMS - Lower ARR2 is superior  Efficacy among the Best-in-Class in relapsing-remitting multiple sclerosis (RRMS)  Selective modulation of S1PR-1/5  Differentiated safety profileLower rates and severity of CV adverse events compared to GilenyaLow rate of GI events and overall discontinuations No reported cases of symptomatic bradycardia or second degree heart blockDiligence focused on 2018 FDA Refuse-to-File letter  Potentially Best-in-Class Safety Profile  Ozanimod  Tecfidera  Plegridy  Aubagio  Copaxone  Avonex  Gilenya  Rebif  Ocrevus  Tysabri 
 
   RRMS is a large patient population with need for efficacious and safe optionsPatients have a strong desire for high-efficacy oral medications with improved safety profileOrals comprise 45% of total salesGilenya (S1P) revenues annualizing at ~$3.3BnOzanimod efficacy profile supports utilization in early lines of RRMS  Significant Opportunity For Safer High-Efficacy Orals in RRMS  Gilenya~35%  Orals~45%  Tecfidera~45%  RRMS WW sales in 2018  Non-orals~55%  Total RRMS market  Aubagio~20%  RRMS oral drugs  ~$23Bn  ~$10Bn  Source: Evaluate Pharma 
 
   Ozanimod (1.0 mg)  Placebo  Ozanimod (0.5 mg)  Ozanimod in Inflammatory Bowel Diseases (IBD): Strong Efficacy and Safety Across Key Endpoints  Source: TOUCHSTONE Trial, a randomized double-blind, placebo-controlled study in 197 patients with ulcerative colitis. Sandborn et al., New England Journal of Medicine (2016); World Journal of Gastrointestinal Pathophysiology  Placebo  Ozanimod (0.5 mg)  Ozanimod (1.0 mg)  Potential Oral alternative to current Injectable Standard of CareComparable efficacy with potentially preferable side effect profile to emerging oral treatments (JAKs)Mucosal healing is an important endpoint – indicates control of gut injury  Fewer SAEs compared to placeboUnlike anti-TNFs, Ozanimod is not likely to have black box warningsUnlike JAKs, not expected to increase risk of thromboembolism  Promising Efficacy in Phase 2 Trial in Ulcerative Colitis Published in the New England Journal of Medicine  Clinical Remission Rate  Mucosal Healing Rate 
 
   Opportunity for First Approval Among S1Ps in IBD  1.5  0.5  0.0  1.0  Disease fully controlled  Patients who progress to advanced therapies (e.g., biologics, novel orals)  Moderate to severe patients  U.S. / EU5 addressable IBD patients (2018)Millions of patients  ~1.2  ~0.5  ~0.2  IBD is a large patient population underserved by current optionsTotal IBD sales ~$17Bn in 2018<50% of patients eligible for advanced therapies are treated given administration burden and side effect profileOnly ~40% of patients treated with advanced therapies are well controlledPotential to expand pre-biologic segmentAutoimmune analogs support use of efficacious orals before biologicsIncremental expansion opportunity of ~700K patients  Source: Janssen, DRG, EvaluatePharma 
 
   RRMS filed in EU and on track to refile in U.S. 1Q 2019Ulcerative Colitis Phase 3 data expected to read out mid-2020Rationale supported by positive Phase 2 data in UC and CD (placebo-controlled and single-arm, respectively) Crohn’s diseases Phase 3 trial underwayEndoscopic clinical improvement seen in Phase 2 STEPSTONE data   Regulatory Path and Clinical Program 
 
   Novel approach to treating patients with anemia demonstrated by positive Phase 3 dataReduced transfusion burden and anemia in myelodysplastic syndromes (MDS)Greater proportion of transfusion burden reduction in beta thalassemiaRegulatory submissions expected for both indications in 1H 2019Potential label expansion opportunities with ongoing Phase 3 trials:First-line MDS regardless of RS status vs. epoetin-alfaNon-transfusion dependent Beta Thalassemia (BT)  Luspatercept Overview  MDS - myelodysplastic syndromes  
 
   First-in-Class Anemia Treatment with Positive Phase 3 Data in Myelodysplastic Syndromes (MDS)  Source: ClinicalTrials.gov, Fenaux et al., ASH (2018), Platzbecker et al., Lancet Oncology (2017), Bajar et al., Blood (2014), Celgene websiteNotes: 1. mHI-E (modified erythroid response): defined as a hemoglobin increase of ≥ 1.5 g/dL from baseline for ≥ 14 days (in the absence of red blood cell (RBC) transfusions) in non-transfusion dependent patients, or, a reduction of either ≥ 4 units or ≥ 50% of units of RBCs transfused compared to pre treatment in transfusion dependent patients; 2. RBC-TI: RBC-transfusion independence > 8 weeks  Significant Improvement in Key Outcome Measures in ESA-exposed low / intermediate risk MDS  Demonstrated benefit to reduce transfusion burden and anemia in Phase 3 MEDALIST trial  Durable responses with a favorable safety profile  Distinct mechanism suggests potential to expand benefit to 1L patients, supported by positive Phase 2 PACE-MDS data (Phase 3 trial ongoing)   RBC-TI2  mHI-E1      Luspatercept  Placebo  MEDALIST data selected as “2018 Best of ASH” due to clinical significance of data 
 
   High unmet need with limited options~90K low-intermediate risk MDS patients with anemia (U.S. and EU5)~90% of patients receive a transfusion and majority become transfusion dependentAlthough erythroid stimulating agents (ESAs) are frequently used, they have significant limitationsApproximately two-thirds of patients relapse or become refractoryESAs carry serious safety concerns (black box warnings) Luspatercept profile and PACE data supports broader opportunity in first line patientsOngoing Phase 3 head-to-head study vs. epoetin alfa (ESA)  Opportunity to Lower Transfusion Burden in MDS  Source: DRG, clinicaltrials.gov, FDA labels 
 
   Luspatercept Demonstrated Reduced Transfusion Dependence in Patients with Beta Thalassemia (BT)  21.4%(n = 48)  Luspatercept(n = 224)  Placebo(n = 112)  4.5%(n = 5)  Patients Achieving ≥ 33% Transfusion Burden Reduction (%)  Source: Celgene investor materialsNote: The BELIEVE trial studied adult patients  Patients Achieved Greater Proportion of Transfusion Burden Reduction  Improvement Across Key Secondary Outcomes  Clinically meaningful reduction in transfusion burden demonstrated during any 12 or 24 weeks of studyWell tolerated with low rate of study drug discontinuation due to adverse events (5%)  Limited Treatment Options for BT Patients  There are ~16K patients with intermediate / major disease, and the vast majority are transfusion dependent (U.S.+EU5) Standard of care is life-long red blood cell transfusions and iron chelationDespite chelation therapy, many patients experience multiple morbidities and increased mortality  P < 0.0001 
 
   Initial 2L MDS (RS+) and transfusion-dependent BT filing expected in 1H2019Ongoing Phase 3 label expansion trials: 1L MDS regardless of RS status vs. epoetin-alfaNon-transfusion-dependent BTAdditional life-cycle opportunities in myelofibrosis and other chronic anemias  Regulatory Path and Clinical Programs in Earlier Lines  PHASE 1  PHASE 2  PHASE 3  Luspatercept Development Plan  Myelodysplastic syndrome  Beta thalassemia  Myelofibrosis  MEDALIST Trial (2L, RS+)  Extension trial  BELIEVE Trial (TDBT)  Ph2 Trial  COMMANDS Trial (1L vs. epoetin alfa)  Extension trial  BEYOND Trial (NTDBT)      Trial Complete     
 
   Industry Leading CAR-T Portfolio Supported by Leading Oncology Commercial Capabilities    CURRENT CAR-T OPPORTUNITY LIMITED BY:  BMS and CELGENE CAR-T OPPORTUNITY ENABLED BY:  THERAPEUTIC PROFILE (SAFETY)  MARKET ACCESS & REIMBURSEMENT  COMPLEX MANUFACTURING & LOGISTICS  LIMITED TO LATE LINE THERAPY              Potential product differentiation supported by clinical data Differentiated market access / reimbursement capabilitiesLeading hematology organization with commercial infrastructure in place to rapidly expand treating centers and referral networksRobust development plans to move CAR-T into earlier lines of therapy  EvaluatePharma  TOTAL CAR-T SALES ARE EXPECTED TO APPROACH $1Bn IN 2019 (~70% YoY growth)BMS AND CELGENE HAVE THE POTENTIAL TO BE THE LEADER IN THE EMERGING ~$15Bn1 CAR-T OPPORTUNITY 
 
   Potential Best-in-Class CAR-T for B Cell malignancies including Diffuse large B cell lymphoma (DLBCL) and Chronic lymphocytic leukemia (CLL)Strong efficacy with 46% complete response ratesPotential superior safety profile with low 1% CRS rateRegulatory submission expected in 2H 2019 in relapsed/refractory DLBCLBroad clinical program across malignancies and earlier lines of therapy 2L transplant eligible and ineligible DLBCL patients  Liso-cel Overview  CRS - Cytokine Release Syndrome 
 
   Strong Efficacy Profile with Significantly Improved Complete Response Rates Relative to Standard of Care   EFFICACYResponse Rate at 6 months  SAFETYCytokine Release Syndrome  ™  ™  ™  ™  Neurotoxicity  ™  ™  U.S. submission expected 2H2019  Data presented to show potential profile of Liso-cel, which is subject to ongoing investigation, within context of other CAR T treatments. Because clinical trials are conducted under widely varying conditions, and CAR T toxicity grading scales differ across studies, adverse reaction rates and response rates observed in CAR T cell therapy clinical trials cannot be directly compared.References: Liso-cel: Efficacy and safety data cut-off May 4, 2018, ASCO 2018 (TRANSCEND NHL-001 Abramson et al); Efficacy (n=37): DLBCL CORE cohort dose level 2 includes - NOS de novo and transformed from FL, ECOG 0-1, high-grade B-cell lymphoma. Safety (n=102): DLBCL full cohort includes - NOS de novo and transformed from any indolent lymphoma, ECOG 0-2. YESCARTA™: Efficacy (n=101): ZUMA-1, ASCO 2017, Neelapu et al. Safety (n=108): YESCARTA Prescribing information. KYMRIAH™: Efficacy (n=93): JULIET, Schuster et al. NEJM, January 2019 . Safety (n=111): KYMRIAH Prescribing Information.   3%  36%  81%  10%  51%  56%  5%  4%  40%  1  1  2  Strong Efficacy & Potential Superior Safety Profile  Precise dose of CD4+ and CD8+  Consistency in cell dose and function compared to other CAR-T products  4-1BB co-stimulation provides predictable CAR-T expansion  Differentiated CAR-T  Maturing data from TRANSCEND NHL study  Safety profile supports outpatient administration 
 
   Opportunity to Improve Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL)  Source: DRG, EvaluatePharma  ~22K relapsed/refractory patients treated per year (U.S. and EU5) Significant unmet exists for relapsed/refractory patients Poor efficacy of historical therapies; ORR <40% and CR <20% mOS is 6-7 months for patients who are refractory or fail stem cell transplant Potential to move into 2L given limitations with standard of carePatients with chemo-refractory disease are considered ineligible for stem cell transplant50% of patients fail transplant with inferior outcomes from existing therapies  SCHOLAR-1 data: Crump et al. Blood 2017 
 
   Impressive CLL Data in Heavily Pre-Treated Population Suggests a Potential New Standard  44%  4%  Liso-cel results in relapsed/refractory CLL (Response rate)  8%  Bendamustine-Rituximab(N=195)  84%  Venetoclax-Rituximab(N=194)  38%  Liso-cel(N=16)      PR  CR  Phase III MURANO Study  Phase I/II TRANSCEND CLL  Median number of prior treatments = 1Prior BTK inhibitor exposure: 1.5-2.5% of patients  Median number of prior treatments = 4.5Prior ibrutinib = 100%Prior ibrutinib and venetoclax = 50%  Source: Celgene investor materials; Seymour et al. N Engl J Med 2018; 378: 1107-1120Note: Data presented to show potential profile of JCAR017, which is subject to ongoing investigation in R/R CLL, within context of R/R CLL treatment landscape. Because clinical trials are conducted under widely varying conditions, response rates in different clinical trials cannot be directly compared  69%  Significant unmet need with limited options after ibrutinib failure  Potential First-in-Class CAR-T in CLL  Pivotal arm of TRANSCEND 004 initiated with patients dosed 
 
   Broad Clinical Development Plan to Advance Liso-cel into Earlier Lines and Additional Indications  Transcend NHL 001 (Ph I 3L + R/R)  Transcend World (Ph II 3L + R/R EU and Japan; 2L R/R transplant ineligible)  Transform (Ph III 2L R/R transplant eligible)  Pilot (Ph II 2L R/R transplant ineligible)  Transcend outreach (Ph II 3L + R/R community centers)  Platform (Ph I/II 3L+ R/R combinations  Transcend CLL 004 (Ph I R/R CLL)  Ped ALL (Ph Ib/II pediatric R/R ALL and NHL)  DLBCL  CLL  ALL        Phase I  Phase II  Pivotal  Source: Celgene investor materials 
 
   First- and Potential Best-in-Class BCMA CAR-TTransformational efficacy in highly refractory multiple myeloma (MM)Complete response rates of ~50% in RRMMRegulatory submission expected in late 2019 / early 2020 Robust development plan with the potential to expand into earlier lines of therapy 2L and 3L+ studies have been initiated  bb2121 Overview 
 
   Transformational Efficacy, Demonstrating a 50% Complete Response Rate in Multiple Myeloma Patients  U.S. submission expected in late 2019/early 2020  Standard Treatment Regimens Across Multiple Myeloma (%)  Emerging bb2121 Profile  ORR 69%-82%  ORR 59%-91%  ORR 29% - 59%  ORR 96%  N= 22  Complete Response PR VGPR        Not for promotional use  bb2121 is being developed by Celgene in partnership with bluebird bio  BCMA is a highly validated target expressed on nearly all Multiple Myeloma cells  CAR-T is an innovative modality to target BCMA  Leverages a state-of-the-art lentiviral construct encoding an anti-BCMA CAR  Novel CAR-T Approach  Transformational Efficacy in Late Line RRMM 
 
   ~260K patients today and expected to reach ~$25Bn + in sales by 2022Patient prevalence in 3L and 4L of ~47KSignificant unmet need for efficacy in relapsed/refractory patients Median overall survival is less than 12 monthsPotential to target high risk patients in earlier lines (2L+)15-20% of patients are considered high risk and have historically poor outcomes  Opportunity to Further Transform Multiple Myeloma   Source: Celgene investor materials; Putnam US and EU5 Epidemiology Evolution research, March 2018; Decision Resources Disease Landscape and Forecast; Epidemiology 2018 from Decision Resources Disease Landscape and Forecast; Kantar Health CancerMPact database; Putnam AssociatesNote: Year of $25Bn+ revenue estimate is 2022  MM Patient Prevalence by line of therapy, US and EU(2017-27)  19  22  21  20  2017  4L+  24  18  23  25  26  27  3L  2L  1L 
 
   Robust Clinical Program with the Potential to Advance into Earlier Lines  PHASE 1  PHASE 2  PIVOTAL  Ongoing Development in Multiple Myeloma  1L phase 2 studies  2L phase 2 initiated  3L+ phase 3 initiated  4L+ pivotal trial fully enrolled  Planning for 2019  KarMMa™2 (MM-002)  KarMMa™3 (MM-003)  KarMMa™ (MM-001)  Key Factors for Success    Celgene leadership in multiple myeloma  Global relationships and commercial infrastructure in hematology / oncology    BMS demonstrated excellence in commercial launch of innovative products        Robust development plans to expand into earlier lines of therapy   
 
   Selective JAK2 inhibitor, potential oral alternative to current standard of care for patients with MyelofibrosisHigh unmet need in patients who are intolerant or relapsed from JakafiAccepted for Priority Review by FDA, PDUFA date of September 3, 2019Potential to address a broader patient population with data from the JAKARTA-1 study  Fedratinib Overview 
 
 High unmet medical need in MF patients that fail or cannot tolerate Jakafi  EFFICACY (JAKARTA2 Trial)  55% of patients achieved splenic volume reduction of ≥35% compared to baseline at week 24  26% of patients achieved total symptom score ≥50% compared to baseline at week 24  Fedratinib: selective JAK2 inhibitor targeting patients who relapsed from or are intolerant to Jakafi in Myelofibrosis  OPPORTUNITY  Not for promotional use  First-in-Class Therapy, Under FDA Review for Patients Resistant/Refractory to Jakafi  >16K prevalent patients in U.S.~$2Bn+ Global Jakafi/Jakavi sales in MF (2024) Limited treatment options – 40% of patients fail Jakafi with no alternatives Accepted for Priority Review by FDA with PDUFA date of September 3, 2019  Source: Evaluate Pharma 
 

   Appendix C  Our March 6, 2019 Investor Presentation 
 
 
 Executive Summary  The Celgene acquisition has clear strategic rationale and represents a compelling value propositionEnhanced product leadership and pipeline: Combined company will be #1 in oncology, top 5 in immunology and inflammation, #1 in cardiovascular; 9 products over $1Bn in annual sales; 6 near-term product launches; robust early-stage pipeline; cutting edge technologies and discovery platformsCompelling value proposition: Greater than 40% accretion to Bristol-Myers Squibb standalone EPS, approximately 10% accretive on a discounted cash flow per share basis and IRR substantially above cost of capitalSpecific, actionable synergies: $2.5 billion of actionable run-rate cost synergies by 2022Attractive price: Value of approximately $55 billion from marketed products and in excess of $20 billion from synergies implies the Celgene pipeline was acquired for a highly attractive price when compared to the aggregate purchase price of $90 billionIdeal timing: Natural exchange ratio at 2-year lows and Celgene P/E near an all-time low when deal was announcedBristol-Myers Squibb has a strong track record of financial and operational outperformanceStrong operating performance: 5-year CAGRs for net revenue and adjusted EPS of 7% and 17%, respectively, both in excess of peer median, with adjusted operating margin up 725 basis points over that time periodConsistent execution: Met or exceeded top line and EPS guidance and estimates on an annual basis each year since 2013Long-term value creation: 10-year TSR of 232% vs. the DRG NYSE Arca Pharmaceutical Index of 123% over the same period1Portfolio transition success: Transitioned portfolio over the last 5 years, with ~60% of 2018 sales coming from new products launched during that periodThe Board and management team conducted a robust process and diligence and are committed to a successful integrationComprehensive process: Prioritized more than 20 transformational and ‘string-of-pearls’ opportunities, and Celgene selected as most attractive opportunityThorough Board oversight: Consistent Board involvement throughout process, with 8 meetings to discuss Celgene opportunityExtensive diligence: 6-month deep-dive analysis and weeks of confidential due diligence provided comprehensive view of Celgene’s opportunities and risksFocused and committed to a successful integration: Complementary nature of businesses, strong team in place to manage integration and rigorous planning approach  Includes dividends. Period from 2/14/2009 – 2/14/2019 
 
 The Celgene Acquisition Has Clear Strategic Rationale and Represents a Compelling Value Proposition 
 
 Consistent with our strategy of delivering value for shareholders by enhancing core franchises and delivering innovative therapies for patientsCelgene pipeline includes 5 differentiated late-stage assets with low clinical risk, expected near-term approvals and incremental value creationExpanded early-stage pipeline and scientific capabilities, adding > 20 Phase 1 and 2 assets and new capabilities in cell therapy and protein homeostasisCreates significant value in excess of purchase price from 1) marketed portfolio, 2) run-rate cost synergies and 3) deep pipeline of late- and early-stage assetsMarketed portfolio offers significant near-term cash flows and strategic leadership position in hematologyValue of marketed portfolio reflects conservative assumptions regarding RevlimidOpportunistically timed given favorable relative valuation of BMS to Celgene~10% accretion to BMS’s standalone DCF value per share, taking into account the issuance of equity to Celgene shareholders>40% accretion to BMS standalone EPS in the first full year post-transaction and accretive in each year through 2025Combined company to grow revenues and earnings in every year through 2025The Celgene acquisition was identified as the most attractive opportunity for shareholder value creation, given risk profile, viability and relatively attractive purchase priceEnhanced business profile with reduced product concentration and significantly improved operating margins  Celgene Transaction Strategically Compelling and Creates Significant Value for BMS Shareholders 
 
 Creates new company with increased scale while maintaining focus and agilityCreates leading Oncology company and adds a premier commercial hematology businessImmunology & Inflammation franchise with greater commercial scale and pipeline depthStronger combined company to address eventual loss-of-exclusivities for Eliquis and Opdivo More diverse and younger portfolio given 6 potential near-term product launchesMaturing Phase 1 / 2 programs to support next wave of launchesStrong balance sheet to pursue external innovationCombined portfolio better positioned to address evolving pricing and access environment   Strengthened Position in Both the Near- and Long-Term 
 
 Celgene Provides 5 Late Stage Products With Near-Term Approvals and Relatively Low Clinical RiskBMS Projected Total Sales from “Big 5” in 2025 Consistent with Street Forecasts  Ph 3 / PivotalComplete  CVR Tied to Near Term Approval  Key Benefits  Current Status      First- and Best-in-class novel anemia drug  U.S. and EU regulatory submissions expected in first half 2019 in 2L MDS and Beta-Thalassemia      Potential to be the first & only medicine for Myelofibrosis patients that don’t respond to, or are intolerant to, Jakafi  U.S. submission accepted with Priority Review by FDA Potential U.S. approval in second half of 2019      Best-in-class cell-therapy for a form of non-Hodgkin (DLBCL) with potential in Chronic Lymphocytic Leukemia (CLL)  U.S. submission expected in second half of 2019      First-in-class cell-therapy for Multiple Myeloma  Currently in pivotal trialsPotential U.S. approval in second half of 2020      Best-in-class selective S1P in relapsing forms of MS and First-in-Class in Inflammatory Bowel Disease  U.S. NDA and EU MAA submissions for RMS planned for Q1 2019  luspatercept   liso-cel (JCAR017)  bb2121  fedratinib  ozanimod  CVR linked to key pipeline assets provides further risk mitigation to BMS shareholders 
 
 Celgene Offers Leading Capabilities in Cell Therapy and 2 Differentiated Late-Stage CAR-T AssetsTransformational Modality with Unprecedented Efficacy  Cell therapy market expected to grow from ~$1Bn in 2019 to >$15Bn in 2024¹Growing expectations for cell therapy given superior efficacy, expected evolution to earlier lines of therapy and improvement in cost / logisticsFirst CAR-T launches from competitors in 2018 reflected initial challenges with access, safety profile, logistics and manufacturing; Celgene’s differentiated assets and hematology infrastructure can address many of these issues Liso-cel is differentiated from currently approved CD19 CAR-T therapies and bb2121 represents a first-in-class BCMA CAR-TBMS will add value to commercial execution of Liso-cel and bb2121 through its proven capabilities in product launch, market access and reimbursement  Potential best-in-class anti-CD19 CAR-T for B-Cell malignancies, with strong efficacy and potential superior safety profile“The data for JCAR017 in difficult to treat patients … continue to impress in terms of both efficacy and safety….We believe a differentiated safety profile could be a significant advantage for JCAR17 among CD-19 CAR-T therapies.” – Leerink  First-in-class anti-BCMA CAR-T with transformational efficacy and substantial lead in late line Multiple Myeloma“bb2121 to become the SOC (standard of care) for multiple myeloma patients who are running out of options…we believe bb2121 could represent a multi-billion dollar global opportunity”– Piper Jaffray  liso-cel (JCAR017)  bb2121  Source: SEC filings, Wall Street researchTotal sales for cell therapy class per EvaluatePharma 
 
   CLL      Liso-celPotential Best-in-Class anti-CD19 CAR-T for B Cell Malignancies   Broad Clinical Development Plan to Advance into Earlier Lines and Additional Indications        PIVOTAL  PHASE II  PHASE I        TRANSCEND WORLD (Ph II 3L+ R/R EU and Japan; 2L R/R transplant ineligible)     DLBCL  PLATFORM (Ph I/II 3L+ R/R combinations)      ALL  EFFICACYResponse Rate at 6 months  SAFETYCytokine Release Syndrome  Safety profile has supported outpatient administration  ™  ™  ™  ™  Neurotoxicity  ™  ™  U.S. submission expected 2H2019  Data presented to show potential profile of Liso-cel, which is subject to ongoing investigation, within context of other CAR T treatments. Because clinical trials are conducted under widely varying conditions, and CAR T toxicity grading scales differ across studies, adverse reaction rates and response rates observed in CAR T cell therapy clinical trials cannot be directly compared. References: Liso-cel: Efficacy and safety data cut-off May 4, 2018, ASCO 2018 (TRANSCEND NHL-001 Abramson et al); Efficacy (n=37): DLBCL CORE cohort dose level 2 includes - NOS de novo and transformed from FL, ECOG 0-1, high-grade B-cell lymphoma. Safety (n=102): DLBCL full cohort includes - NOS de novo and transformed from any indolent lymphoma, ECOG 0-2. YESCARTA™: Efficacy (n=101): ZUMA-1, ASCO 2017, Neelapu et al. Safety (n=108): YESCARTA Prescribing information. KYMRIAH™: Efficacy (n=93): JULIET, Schuster et al. NEJM, January 2019.  Safety (n=111): KYMRIAH Prescribing Information.   TRANSCEND NHL 001 (Ph I 3L+ R/R)    TRANSCEND CLL 004 (Ph I R/R CLL)    TRANSCEND OUTREACH (Ph II 3L+ R/R community centers)    TRANSFORM (Ph III 2L R/R transplant eligible)    PILOT (Ph II 2L R/R transplant ineligible)       3%  36%  81%  10%  51%  56%  5%  4%    Ped ALL (Ph Ib/II pediatric R/R ALL and NHL)   40%  1  1  2  Strong Efficacy & Potential Superior Safety Profile 
 
   bb2121 Anti-BCMA CAR-T with Transformational Efficacy in Late Line RRMM  Potential U.S. Approval 2H 2020  Standard Treatment Regimens Across Multiple Myeloma (%)  Emerging bb2121 Profile  ORR 69%-82%  ORR 59%-91%  ORR 29% - 59%  ORR 96%  N= 22  Complete Response VGPR PR              PIVOTAL  PHASE II  PHASE I        Phase II studies planned in front-line setting  Phase II study initiated in 2nd line setting  Phase III study in 3rd line+ initiated  Pivotal trial in late line fully accrued  In planning for 2019        KarMMa™2 (MM-002)  KarMMa™3 (MM-003)  KarMMa™ (MM-001)    MULTIPLE MYELOMA          Not for promotional use  bb2121 is being developed by Celgene in partnership with bluebird bio 
 
 Celgene Provides a Significantly Expanded Early Stage Pipeline and New Technology Platforms  Transaction provides BMS with >20 Phase 1 and 2 programsNew capabilities in cell therapy and protein homeostasisStrongest position in BCMA: 5 programs total, first expected BCMA launch product (bb2121), and 3 modalities (CAR-T, TCE, and ADC) Early stage pipeline and research capabilities a key focus area of confidential due diligenceSignificantly broadened pipeline enhances sustainability of BMS long-term growthSeveral near-term read-outs from high potential assets among Phase 1/2 portfolio in 2019/2020  Source: SEC filings  JCARH125 (BCMA CAR T)  CAR-T focused on R/R MMEstimated pivotal study in 2019  CC-92480 (CELMoD)  R/R Multiple MyelomaEstimated pivotal study in 2019  CC-93269 (BCMA TCE)  R/R Multiple MyelomaEstimated pivotal study in 2019  CC-90009 (CELMoD)  CelMod focused on AMLEstimated pivotal study in 2019  CC-90011 (LSD1 Inhibitor)  Phase I study for solid tumors  CC-90002 (CD47 Mab)  Phase I Study targeting NHL  High Potential Agents and Pipeline Assets to Watch  CC-220 (CELMoD)  R/R Multiple Myeloma  bb21217 (BCMA CAR T)  CAR-T focused on R/R MMPhase I updates in 2019/2020 
 
 Significant Value Creation Opportunity From Celgene Pipeline  More than 80% of transaction value supported by currently marketed products and synergies aloneValue of currently marketed products reflects Revlimid assumptions which are more conservative than those of sell-side analystsImplied cost of “Big 5"pipeline highly attractive given 5 late-stage pipeline assets (“Big 5”), >20 Phase 1/2 assets and leading cell therapy and protein homeostasis platforms. Significant value creation expected in excess of cost  Celgene Components of Value  In $Bn    >80% of Transaction Value  Source: SEC filingsEquity purchase price plus net debt 
 
 Celgene Provides a ‘String-of-Pearls’ in One Transaction and at an Attractive Valuation  Traditional ‘string-of-pearls’ strategy difficult, longer to execute and at significant premiumsRequires successfully identifying and winning multiple potentially competitive processesStreet estimates for Celgene pipeline revenue in FY5 (2023) of approximately $5Bn  Public Biopharma Acquisitions from 2018 to Current(Enterprise Value $2Bn-$20Bn)  Source: Capital IQ, SEC filings  Implied Enterprise Value / Fiscal Year 5 Revenue Multiple  Premium to Unaffected 
 
 Analysis Based on Conservative, Risk-Adjusted Projections for Celgene  Source: Capital IQ, SEC filingsCapital IQ median as of 01/02/2019    Consensus1    Celgene Blended Mgmt. Case    BMS Projections for Celgene  Extensive due diligence conducted on Revlimid IP estateBMS base commercial assumptions below both Street consensus and Celgene management projections, primarily driven by RevlimidBMS evaluated range of scenarios including early-at-risk launch, which remains low probabilityTransaction creates value to BMS shareholders across all scenarios evaluatedEstimates include pipeline contribution on risk-adjusted basis  2019E – 2023E Celgene Projected Revenue  Revenue, $Bn 
 
 Significant Near-Term Free Cash Flow Generation  2020E – 2023E Pro Forma BMS + Celgene Cumulative Free Cash Flow  In $Bn  Source: SEC filings  Transaction significantly enhances cash flow generation, enabling rapid deleveraging and providing flexibility for continued business development and return of capital  Pro Forma Credit Profile1  Debt/EBITDA  <1.5x  Debt/EBITDA pro forma for the transaction. All figures are presented on a Non-GAAP basis. These figures are based on numerous assumptions and estimates, including information provided to the Company by Celgene, as adjusted by the Company. The figures were not prepared with a view toward public disclosure, and the inclusion of the figures should not be regarded as an indication that any of the Company, Celgene or any other recipient of this information considered, or now considers, it to be necessarily predictive of actual future results. None of the Company, Celgene or their respective affiliates assumes any responsibility for the accuracy of this information. The non-GAAP measures are not meant to be considered in isolation or as an alternative to the corresponding measures and should be read only in conjunction with our reported results prepared in accordance with GAAP. In addition, the non-GAAP measures may not be the same as or comparable to similar non-GAAP measures presented by other companies due to possible differences in method and in the items being adjusted 
 
 ~$2.5Bn of Cost Synergies Provide for Over $20Bn in Value  Sources of Synergies  % of Total Synergies  Source: SEC Filings  Overview of SynergiesSynergies represent $2.5Bn in sustainable long-term cost savings Represents ~13% of combined company OpEx; Well within biopharma precedents To be generated from both BMS and Celgene operationsSources of OpportunityCommercial efficiencies in combined Oncology and Immunology & Inflammation franchisesOptimizing research and early-stage portfolio and reducing overlapping resourcesLeveraging BMS biologics capabilities for new Celgene biologic products 
 
 BMS Equity Issued at Favorable Relative Valuation, Creating Value for BMS Shareholders  1.3x  1.8x  BMS / Celgene Natural Exchange Ratio at Two-Year Lows1  January 1, 2017 to January 2, 2019  Opportunistic timing given favorable relative valuation of BMS versus Celgene equity  Source: Capital IQ, SEC FilingsDefined as Celgene stock price divided by Bristol-Myers stock pricePer Bristol-Myers Financial Advisors, as disclosed in S-4. Midpoint DCF value  Materially accretive to BMS DCF Value/Share, accountingfor BMS share issuance  2-year Average  Transaction Enhances BMS’s DCF Value per Share2  
 
 Highly Attractive Purchase Price  Pre-Announcement Celgene Analyst Price Targets Higher than Offer PriceSeptember 3, 2018 to January 2, 2019  6.7x  Celgene NTM P/E 1  Source: Capital IQConsensus estimate; not burdened by stock-based compensationExcludes CVR valueTransaction was withdrawnBased on final publicly announced offer  17.1x  9.9x  Implied P/E based on 1/2/2019 Offer Price2  9.9x NTM P/E paid represents substantial discount to even the lowest relevant precedent multiple (12.8x)  AnnounceDate  Acquiror  Target  NTM P/E  5/8/2018  Takeda  Shire  12.8x  1/11/2016  Shire  Baxalta  21.3x  11/23/20153  Pfizer  Allergan  27.2x  11/17/2014  Actavis  Allergan  27.5x  7/18/20143  AbbVie  Shire  26.0x  5/18/20143, 4  Pfizer  AstraZeneca  21.6x  3/9/2009  Merck  Schering-Plough  14.0x  1/26/2009  Pfizer  Wyeth  13.7x  4/26/2004  Sanofi  Aventis  19.0x  Median        21.3x  $67  Celgene Stock Price  Offer Price as of 1/2/19  Celgene Price Target  $94  $112  $105  $102.42  Celgene NTM P/E Declined Over TimeJanuary 1, 2017 to January 2, 2019  Acquisition Multiple Favorable vs. Precedent Transactions NTM P/E vs. Precedent Transactions 
 
 Combined Company to Grow Revenues in Each Year Through 2025  Pro Forma Revenue are pro forma for the transaction and for 2019 are based on full year contribution for purposes of comparison. These figures are based on numerous assumptions and estimates, including information provided to the Company by Celgene, as adjusted by the Company. The figures were not prepared with a view toward public disclosure, and the inclusion of the figures should not be regarded as an indication that any of the Company, Celgene or any other recipient of this information considered, or now considers, it to be necessarily predictive of actual future results. None of the Company, Celgene or their respective affiliates assumes any responsibility for the accuracy of this information. The non-GAAP measures are not meant to be considered in isolation or as an alternative to the corresponding measures and should be read only in conjunction with our reported results prepared in accordance with GAAP. In addition, the non-GAAP measures may not be the same as or comparable to similar non-GAAP measures presented by other companies due to possible differences in method and in the items being adjusted  Pro Forma Revenue1  Revenue, $Bn  Eliquis growth in Atrial Fibrillation & VTE20+ potential new indications for Opdivo/Yervoy including in adjuvant6 potential launches from late-stage in next two yearsCombined 50 Ph 1/2 Assets to deliver next set of potential medicines  Future Growth Drivers 
 
 Significantly Expanded Earnings Power of Combined Company  Source: SEC filings    BMS Pro Forma Net Income    BMS Standalone Net Income  Transaction more than 40% accretive to EPS in first full yearAccretive to EPS in all years though 2025Significant free cash flow from combination to provide flexibility for future share buybacks to further enhance EPS accretion  2020E – 2023E BMS Projections  Cash Net Income, $Bn 
 
 Celgene Enhances Overall Business Profile of BMS  Meaningfully enhanced product diversification and margin profile  Includes run-rate synergies of $2.5Bn  Top 3 BMS Products as % of Standalone and Pro Forma Revenue  2025E Revenue  Standalone vs. Pro Forma Margins  2018A Non-GAAP Operating Income Margin 
 
 Bristol-Myers Squibb Has a Strong Track Record of Financial and Operational Outperformance 
 
 Robust Record of BMS Operating and Financial Performance  While we are not satisfied with recent share price performance, largely driven by dynamics in first-line lung cancer, the Bristol-Myers Squibb team has generated a track-record of strong operating and financial results over the last five years: Successfully transitioned Company’s portfolio through losses of exclusivity (LOEs), with approximately 60% of 2018 sales coming from new products launched during that periodOpdivo has been the most successful oncology launch based on the cumulative sales in the first four years and currently has the leading share in most approved indicationsEliquis achieved the leading share in the novel anticoagulant market overcoming two prior entrantsSignificantly improved operating margins by 725 basis points through company operating model transformationDelivered adjusted operating income compounded annual growth rate (CAGR) of 13.1% and adjusted earnings per share CAGR of 16.9%BMS is well positioned to integrate, deliver synergies and bring innovative therapies to patients and improve margins 
 
     Diversified Specialty BioPharma  Best of BIOTECH  Best of PHARMA    INNOVATION  Focused and Integrated  The Best PEOPLE helping patients in their fight against serious disease  Bristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm  Our Strategic Foundation 
 
 Proven Success in Transitioning Portfolio Over Time   BMS Historical Total Sales ($Bn)  Contribution of Sales (%)  +$14Bn  Established Brands  Other Prioritized Brands  Prioritized Brands Launched Since 2011            Other  +$2Bn  ($9Bn)  +$6Bn  Management has a proven track record of success in transitioning a mature portfolio and returning to growthBeginning in 2011, loss of >$7Bn in sales for the blood thinner Plavix represented one of the largest patent cliffs in history, as defined by % of company salesOver 5-year period from 2013 to 2018:BMS grew revenues from $16Bn to $23Bn, despite losing >50% of 2013 sales due to LOEs>$15Bn incremental sales from new products, replacing ~165% of 2013 revenues lostComposition of 2018 sales highlights product freshness:59% from products launched since 2013165% from products launched since 2011  ∆’13-’18:  Through solid execution, BMS almost doubled the amount of sales that were lost primarily from loss of exclusivity over the last 5 years  Represents combined sales contribution in 2018 of Eliquis, Opdivo and Empliciti 
 
   Revenue Growth 1  BMS Has Outperformed Peers Across Multiple Metrics Over Last 5 Years  Adj. Operating Margin Improvement 1, 2  Adj. EPS Growth1  % CAGR  Change in bps; 2013 - 2018  % CAGR  3  3  3  Sources: Company filings & Capital IQMetrics shown based on as adjusted reported financials; historical financials not shown pro forma for acquisitions or divestituresAdj. operating income defined as non-GAAP gross profit less SG&A and R&D expensesPeer group defined as AbbVie, Allergan plc, Amgen, AstraZeneca, Biogen, Gilead, GlaxoSmithKline, Johnson & Johnson, Eli Lilly, Merck, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi 
 
 Products sourced through acquisitionof for $1.8Bn    $6.7B     $1.3B     $2.7B     $2.0B   Track Record of Portfolio Development Through Both Internal Investment and Acquisitions  Celgene acquisition is an extension of historical balanced approach to delivering new medicines to patients    INTERNAL    EXTERNAL  2018 Sales:  2018 Sales:    $6.4B   2018 Sales:  Acquired from DuPont in 2001 as a preclinical compound; developed at BMS and partnered with Pfizer  Internally Developed 
 
 Eliquis 3rd to enter the novel anticoagulant (NOAC) market in 2012Able to push to the leading position through solid execution and a differentiated clinical profile#1 NOAC$6.4Bn of Eliquis sales in 2018 showing 32% growth  Successfully launched OpdivoDespite being 2nd to enter US anti PD-1 market at the end of 2014, established a leading position16 FDA approved indications within 4-years post launch>400 global approvals$6.7Bn of Opdivo sales in 2018 showing 36% growth  Focus on profitability allowed for margin expansion despite significant number of new launchesCommercial focus on top brands and key marketsFocused global manufacturing supply chainStreamlined enabling functions  Commercial Excellence Extends Across Multiple Strategic Objectives Over the Last 5 Years  Managed multiple concurrent strategic initiatives to deliver top-line growth and margin expansion resulting in strong EPS growth    IMMUNO-ONCOLOGY    ELIQUIS    COMMITMENT TO MARGIN EXPANSION 
 
   I-O Commercial and Development Success  Top Oncology Products: Cumulative Sales in 4 Years Post Launch  US Sales ($Bn)  Approvals Post-Launch              0  2  4  6  8  10  Opdivo  Avastin  Taxotere  12      14  16  in Yearsin the U.S.  Approvals   16  4  Source: IQVIA NSP $ Sales US only 
 
 Lung  2L Leadership with 28% BMS I-O share3L+ SCLC Leadership with 68% BMS I-O share  Melanoma  1L Leadership with 60% BMS I-O shareAdjuvant Leadership with 77% BMS I-O share  Renal cell Carcinoma  1L Leadership with 44% BMS I-O share2L Leadership with 52% BMS I-O share  Head & Neck  Post platinum 18% BMS I-O share  2L Hepatocellular Carcinoma  2L Leadership with 57% BMS I-O share  Despite Competitive Intensity, BMS Continues to Lead in Key Tumors where Opdivo is Approved   6 Approved PD(L)1s with a Combined43 Indications Across 14 Tumors In ~ 4 years  BMS I-O Leadership Across Key Tumors   U.S. Approval  Commercialization  Product  Sep. 2014      Dec. 2014      May. 2016      Mar. 2017      May. 2017      Sep. 2018        Ongoing Competitive Execution Strategy:Develop launch-like plans to key competitive eventsLeverage analytical capability to quickly assess and pivot in marketDiscipline to stay focused where we are playing  BMS I-O share includes Opdivo and Yervoy share in combination and/or monotherapy  BMS Share Source: BMS Share Source: AIRxShare Jan-19 (8WRA for NSCLC, 13WRA for all other tumors); SCLC 3L+ share is for the month of Dec-18. CRC, HL, Bladder and stage III unresectable NSCLC shares are not available to BMS; Overlapping approvals with Opdivo (total 16 indications across 9 tumors): Keytruda approvals in: Adjuvant and Metastatic Melanoma, 2L Lung, PP H&N, 2L HCC. Tecentric approvals in: 2L Lung 
 
 Eliquis Annual Sales  $Bn; 2013 - 2018  5 Year CAGR: +113%  +430%  +140%  +80%  +46%  +32%  Annual Growth:    #1 NOAC(Mar’15)  #1 OAC(Feb’16)  Evolution of OAC Market Share in Atrial Fibrillation (AF)1  January 2013 – September 2018  Chart represents New-to-Brand (Naïve+Switch) Rxs (NBRx). Eliquis, Xarelto, Pradaxa and Warfarin factored for AF. Savyasa represents all approved indications. Pradxa 110 mg not captured in NBRx. Source: IMS-NP MD (Custom). Retail Only  Excellent Commercial Execution & Differentiated Clinical Profile Have Driven Eliquis to Become #1 NOAC Globally  Eliquis was the 3rd product to enter the novel anticoagulant (NOAC) market in 2012Despite 3rd to market entry, effective execution capitalizing on superior clinical profile has driven leadershipDual benefit of higher efficacy and lower bleeding rates Generated >$6Bn sales in 2018 and currently represents:#1 NOAC Worldwide#1 Oral Anticoagulant (OAC) in major markets#1 US Prescribed CV Branded MedicineSales results have exceeded or achieved consensus estimates in 19 of 24 quarters since 1Q 2013 (79%)Strong account management across hospitals, cardiology, PCPs, networksIndustry leading use of Real-World Data  59%  24%  23%  3%  <1% 
 
 Commitment to Margin Expansion With Ongoing Operating Model Transformation  Company operating model transformation progress continues – originally announced 3Q 2016Significant operational changes have been successfully implemented while continuing to maintain favorable R&D productivity metrics and beating internal and external commercial performance expectationsEfficiencies and redeployment of resources have enabled up-investments in key value-driving areasUp-investments across R&D to expand Oncology portfolio (e.g., Opdivo life cycle management and next-generation compounds) and business development in areas such as Translational Medicine and Digital HealthRevenues have continued to grow at a strong rate, despite slowdown in OpEx growth2016-2018 revenue compound annual growth rate (CAGR) of ~8% vs OpEx CAGR of ~1%Company has achieved ~$1.4Bn increase in adjusted operating income over 2-year period since 2016$1.6Bn increase in gross margin from portfolio growth and sourcing optimizationExecution of transformation targets with net reduction in MS&A (-$0.4Bn) allowing for redeployment in R&D (+$0.7Bn)Recently announced divestiture of UPSA consumer health will further simplify company structure and improve margins 
 
   Net Sales, $Bn  Strong Track Record of Financial Results…  $16.4  $15.9  $16.6  $19.4  $20.8  $22.6  CAGR6.6%  Adj. Operating Income1, $Bn  CAGR13.1%  Adj. Operating Margin1 %  Adj. EPS  +725bps  21.1%  21.8%  23.4%  25.9%  25.0%  28.3%  $3.5  $3.5  $3.9  $5.0  $5.2  $6.4  $1.82  $1.85  $2.01  $2.83  $3.01  $3.98  CAGR16.9%  Source: Company FilingsDefined as non-GAAP gross profit less SG&A and R&D expenses 
 
 …With a High Degree of Execution Consistency…  Adjusted EPS Results Have Beat or Met Consensus Expectations in 92% of Quarters Since the Beginning of 2013 (22/24 Quarters)1  Quarterly EPS ($ / share); 1Q 2013 – 4Q 2018                                                  Sales Have Beat or Met Consensus Expectations in 88% of Quarters Since the Beginning of 2013 (21/24 Quarters)1  Quarterly Sales ($Bn); 1Q 2013 – 4Q 2018                                                  Actual vs Consensus:  From both an internal and external perspective, BMS has successfully met or exceeded top-line and EPS guidance & estimates on an annual basis in each year since 2013  Actual vs Consensus:  Beat/Meet1:  Beat/Meet1:  Sources: Thomson, Company FilingsBeat/Meet in a given quarter defined as actual results greater than or equal to Thomson consensus median estimates 
 
 Immuno-Oncology (Opdivo + Yervoy) Quarterly Sales Since the Beginning of 2013  Quarterly Sales ($Bn); 1Q 2013 – 4Q 2018  Eliquis Quarterly Sales Since the Beginning of 2013  Quarterly Sales ($Bn); 1Q 2013 – 4Q 2018  Y-o-Y Growth:  Y-o-Y Growth:  Source: Company Filings  …And Sustained Growth in Key Global Franchises 
 
 The Board and Management Team Conducted a Robust Process and Diligence and Are Committed to a Successful Integration 
 
 BMS has a regular process to actively evaluate strategic opportunities to create long-term value for shareholdersPrioritized more than 20 opportunities in early 2018, and narrowed down over time to focus on the 7 best opportunitiesOpportunities included 'string-of-pearls' strategies as well as other large transformative transactionsExtensive involvement of Board of Directors, with the assistance of multiple outside advisorsCelgene was identified as the most attractive option in September 2018 BMS performed extensive due diligence based on 6 month deep dive analysis and weeks of reviewing confidential informationSubstantial knowledge of Celgene based on prior interactions and regular tracking of fundamental developmentsDeep dive analysis utilized multiple market models, financial forecasts and sensitivities for key assets Thorough assessment of ongoing challenges to IP estate with external expert advisors Evaluated risks and opportunities for late-stage clinical and early pipeline programs Thorough confidential diligence under NDA, including extensive diligence on pipeline and IP estate, and detailed evaluation of Celgene assets and capabilities Extensive discussions with Celgene regarding the ongoing litigations and potential outcomes enabled BMS to develop a fully-informed forecast for RevlimidFinal transaction terms were the result of careful consideration of diligence findingsCVR utilized to mitigate risk of approval for liso-cel (JCAR017), bb2121 and ozanimodBMS is focused and committed to a successful integrationComplementary nature of businessesStrong team in place to manage integrationRigorous planning approach  Acquisition is the Result of a Thorough and Comprehensive Process 
 
    7 companies prioritized for deep dive analysis based on additional financial and strategic criteriaIncluded both transformational and 'string-of-pearls'  77 biopharma opportunities identified;22 prioritized for assessment based on strategic fit  Celgene identified as lead opportunity based on strategic and financial criteriaContinued assessment of ‘string-of-pearls’ opportunities as an alternative  The Celgene Acquisition Resulted From a Robust Strategic Review  Given the scarcity of attractive biotech opportunities, high premiums paid in bolt-on acquisitions, a longer timeline, and the likelihood of competitive auctions that reduce the probability of prevailing, BMS determined that acquiring Celgene’s Big-5 late-stage pipeline, plus its 22 Phase 1 and 2 clinical programs would represent a bundled 'string-of-pearls' that in totality offers a greater value creation opportunity than other strategic alternatives  Continued deep fundamental assessment of Celgene based on public information  Identified 6 franchise options, but of limited strategic and financial impact  Early / Mid-2018  June 2018  Sept 2018  Oct/Nov2018  Nov/Dec2018  Jan2019  Followed by rigorous confidential due diligence process  BoD approval and announcement  Alternatives Considered  Considered 'string-of-pearls' and transformational strategic M&A opportunities  Parallel assessment of asset swaps and joint ventures with peer companies        The Board held eight meetings between June 2018 and January 2019 to discuss the merits of the Celgene opportunity 
 
 Robust Diligence Process on Celgene Opportunity  Work led by ~25 BMS senior leaders and their teams across functional areas and supported by subject matter experts and financial and legal advisorsConducted assessment of markets and drivers of key assets and indications based on competitive intel, primary research, etc.Deep dive reviews of multiple market models and financial forecasts, including deep IP assessment with external expertsDeveloped forecast and leverage sensitivities / scenarios to assess value creation opportunities and potential risksAssessed Celgene capabilities and infrastructurePreliminary synergy estimates in line with precedent transactionsIdentified key questions to be assessed in confidential diligence  Team expanded to ~40 BMS senior leaders and their teams, in addition to expert consultants, financial and legal advisorsEvaluated Celgene assets and capabilities in comparison to prior deep dive analysisConfidential assessment of pipeline opportunities and risks, including ozanimod regulatory interactions, CAR-T data and manufacturing capabilities, and research and early development programsFull review of ongoing IP litigation, and other legal reviewsExtensive document exchange and review in data roomIn-person and telephonic due diligence meetings across senior leadership and subject matter experts representing all functional areasCharacterized and validated potential synergies, identified key risks and mitigation strategies  Deep Dive Analysis(June – Late November)  Confidential Due Diligence(Late November - January) 
 
 Revlimid IP Was a Key Focus of Due Diligence  BMS and its legal advisors conducted an extensive review of the entire Revlimid patent estateReceived access to this non-public information prior to the beginning of other confidential diligence Reviewed the non-public, unredacted Natco agreementExtensive discussions with Celgene regarding the ongoing litigations and potential outcomesDeveloped multiple scenarios based on litigation, IPR and settlement processConsequently, forecasts for Revlimid are fully informed based on information not available to the publicWhile the outcomes are uncertain, believe that the outlier scenarios are unlikelyAs communicated previously, the base model on Revlimid sales and generic entry is more conservative than consensus  On February 11, 2019, the USPTO denied requests by Dr. Reddy’s Laboratories to institute inter partes reviews of Celgene’s Revlimid MDS patents 
 
 Post-NDA Diligence Process Consistent With Precedent Transactions  NDA Signed  IP Diligence Begins  Management Presentation  11/23/18  41 days prior to announcement  11/28/18  36 days prior to announcement  12/13/18  21 days prior to announcement    All Completed Acquisitions of Public Biopharma Companies Over $40B in the Last 10 Years  +  +  Source: Company filings  4/22/18: NDA signed (16 days prior to announcement)4/24/18: Shire issues press release stating it has agreed to engage in discussions / due diligence based on revised Takeda offer5/8/18: Announcement date  1/15/09: NDA signed (53 days prior to announcement)2/22/09: In the days that followed, companies began due diligence3/9/09: Announcement date  1/16/09: NDA signed / due diligence initiated1/26/09: Announcement date    +  +  +  11/5/14: NDA signed / due diligence initiated11/17/14: Announcement date  14 days of due diligence  12 days of due diligence  15 days of due diligence  10 days of due diligence 
 
   BMS is Focused and Committed to a Successful Integration  Complementary nature of businessesNot a traditional big pharma, high-overlap dealStrong team in place to manage integrationTop priority of leadershipFull-time integration leads appointed for each company and for each functional areaExperienced executives and external advisorsCross functional teamsRigorous planning approach Manage risks and interdependenciesMaintain business continuityRetain critical talent and capabilitiesInformed by comprehensive diligence  Integration Team  BMS  Celgene  Executive Leads  Charles Bancroft  Joseph Hand  R&DGPSCommercialHRFinanceITProcurementSite OptimizationStrat / BD / Alliance MgmtBI&ALegal / ComplianceCorporate Affairs  Integration Business Units & Enabling Functions 
 
   Complementary Organizations – Streamlined Integration Process  BMS  Celgene  Commentary  Source: Company filings and websitesBMS’s principal executive office per SEC filings is New York, NYPro forma for divestiture of 1,500 USPA employees; BMS reported 23,300 employees in its 2018 10KPro forma for divestiture of UPSAExcludes 2 cell therapy processing plants  Complementary leadership in oncologyBolsters position in immunology  Oncology (IO / Solid Tumors)ImmunoscienceFibrosisCardiovascular  Oncology (Hematology)Inflammation & Immunology  Alignment of Core Values  Creating Innovative Medicines  Scientific Excellence  Integrity  Transparency  Diversity    New Jersey  Geographic proximity  New Jersey1  8,852  21,8002  Lean employee base from each company  Number of Employees  Proximity of key R&D hubsOverlap in NJ, Cambridge, and San Francisco  5  3  Main US Location / HQ  Integration of lean manufacturing infrastructure  44  63  Key Therapeutic Areas  R&D Hubs  Manufacturing Footprint  Patient-Centric 
 
 Director  Director Since  Experience  Giovanni Caforio, M.D.  2014  Chairman of the Board and Chief Executive Officer, Bristol-Myers Squibb   Vicki L. Sato, Ph.D.  2006  Lead Independent Director, Bristol-Myers Squibb; Independent Chairman of the Board, Denali Therapeutics; Former Professor of Management Practice and Molecular and Cell Biology at Harvard University  Peter J. Arduini  2016  President and Chief Executive Officer, Integra LifeSciences Holdings Corporation  Robert J. Bertolini  2017  Former President and Chief Financial Officer, Bausch & Lomb; Former Chief Financial Officer, Schering-Plough  Matthew W. Emmens  2017  Former Chief Executive Officer and Chairman of the Board, Shire; Former President, Chief Executive Officer and Chairman, Vertex Pharmaceuticals; Former Chief Executive Officer, Astra Merck  Michael Grobstein  2007  Former Vice Chairman, Ernst & Young LLP  Alan J. Lacy  2008  Trustee, Fidelity Funds; Former Chairman, Dave & Buster’s Entertainment   Dinesh C. Paliwal  2013  President and Chief Executive Officer, Harman International  Theodore R. Samuels  2017  Former President, Capital Guardian Trust Company  Gerald L. Storch  2012  Chief Executive Officer, Storch Advisors; Former Vice Chairman, Target; Former Chairman and Chief Executive Officer, Toys “R” Us; Former Principal, McKinsey & Company  Karen H. Vousden, Ph.D.  2018  Chief Scientist, Cancer Research UK; Former Chief Executive Officer, Beatson Institute for Cancer Research  Bristol-Myers Squibb Board of Directors  Highly Experienced, Independent Board  10 of 11 directors are independent and 5 new independent directors added in last 3 years  
 
 Board and Governance – Relevant Experience and Accountability  10 / 11 directors independent (91%)Strong Lead Independent Director with robust responsibilities and oversight5 new independent directors added in the past 3 years1 Average tenure of 5.5 years vs. S&P average tenure of 8.1 yearsAnnually elected directorsAdopted proxy access  Source: Company filings, 2018 Spencer Stuart Board IndexNominated three directors following discussions with JANA Partners in 2017  Healthcare  Public CompanyCEO/CFO  Financial  Risk Management  Sales & Marketing  Academia/Non-Profit  International  Science / Technology/ Innovation  Director Skills and Experience  Corporate Governance Highlights 
 

 GRAPHIC 2 s002621x38_425slide1.jpg begin 644 s002621x38_425slide1.jpg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end GRAPHIC 3 s002621x38_425slide2.jpg begin 644 s002621x38_425slide2.jpg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�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end GRAPHIC 4 s002621x38_425slide3.jpg begin 644 s002621x38_425slide3.jpg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

,_&$FO6;FW@<6QV;Y9<+_'@!5!.[Y@ 2"<<@@<&CQW_R"+/_ M +=__1+4 >G11"$!% "J , < #H!7"Z/_P ARZ_Z]U_E#7>5P>C_ /(< MNO\ KW7^4-, UC_D.6O_ %[M_*:M3XG?\@Z;_MG_ .C4K&\<.^C7]OK!0O#' M&4?8#E>67).,#/F#;DC<01QUJOXC\:1^);"[$*LJQ"#E\ DO+TP">!MZYYST M&.4 WQM=-#HULJG D6W5N!R!&6Q^:@\>GI5R+4];A 1;6$*H !4 < ";@ M"K]QX;'B'2X+;(#B"%D)S@,$'7'8@D=\9S@D"LG3_B8VBJ+3489%EC4#<,,7 MP2NX[B/3[P+!CDC'2@"&/P]?ZY>)<7T0CC\F2)C&R<*Z2#.-[G.7^GM3])FU M+P=']F:W%Q I.TPDELM\W8%MH.>J#D_>Q@&[;_$>;5F;[';.8U60^8RLP+)$ MS!,)P"7VC[Q)!Z D88GQ>CMR8[J"6*13]T -P0""=VP@G/3'3!SS0!O>$_&T M/B0$1Y610"R-C/;)!'5<\9X/3(&1GH:X+P-#+JMW/K4D9B26-%16YW<)E@2% M)&%&#MP=W!X-=[3 X_Q7XXDT^9=.LXQ+3\JY/ (!!SM!)R5"C#9(S6'J MUGK,UO+-/+&D9CD+Q84L%P\O_ * :R_AE_P @^'_MI_Z,>N>UKXC'6X)8+*"1@8G$CR !44J5<-C85'WGDSG*M_ M=KUJO)=%\90^&[R^\Y7/FW#8V!3]UY,YRR_WJ&!O?\*:L_[\W_?2?_$5UNMZ M)%K41MIQE3T(ZJ>S ]B/_K'()%6?E&[^, M=^,$J"Q.X CH_BU(;.Q6&/"HTJ(5 &T*S #C@ J.F.F.E6-5\ I:P(VGC9= M6_,;Y 9C_$&.,-N&>#QGCA"13+D)X\LC!D)*[#5DLWDO)HS%A"Z +OY9<#*Q@9#8SAL<=35IM2?P/>W$LT;/;73[M MZKT)W, .=N02P()!(&X8'!9XR\82:[9N;>!Q;'9OEEPO\>,* 3N^8 $@G'(( M'!I +X[_ .019_\ ;#_T2U>GUY?X[_Y!%G_VP_\ 1+5ZA3 X/2/^0Y=?]<%_ ME#1\(_\ 289[Q^99IVWMTSA0W0<#EVZ =?84:1_R'+K_ *X+_*&LZ'4G^']Q M) \;-8RON1E7[I8< ,3R1C:0QR0NX8Z, =+\3/\ D'S?]L__ $8E<7J-U<&? M3HK=%D=+.-T1P-NXH=QR2O(" CG@@$<]9_&'CEO$%K(EM"_D#;YDLF !AU^4 M $C.2O'YI;:RU6SYGMH(LK\V74*#@8(SC)RHP6#$9R "@+7] MKZY_S[0_]]#_ ./58^'NBW5C)=7%V@1KAU8892,Y-XISNRK# M(RN)8_$,9N(0P57*_. #D 'L3QS M6O2&%%%% !1110(***SO$&N)HD+7,A'R@[03C :!FE17/: M-XHDO+9]1GA,4:H74;][LJ@DG!5< X^7)YZ\#!.EH6LIK4*W<8(1]V P /RL M5/0D=1ZT 7Z*P;/Q3]IOI=+V8\F,/OW9SD(<;<M'A_QB=2N9=.EB,.0<\<9 .FHKGO%GC:'PV ),M(P)5%QGO@DGHN>,\GK@'!Q@ MR?$V>U'F3V,J1@C6AU-0WEA';! WX MCW \9(S\IQS7,_\ "Y;/^Y-_WRG_ ,, MD[6!;D D9^6-AGU )P>,UM>$_'T/B0F)%9)%0,58 CL#A@>0"1U )R..N #I M:XKXLZ?)?6J)"C.PG4X12QQL<9P >.:T-(\9'5;N6QCB(2 L&D9NZG;C:%(R M6SC+#*@GJ,5D0?$R6\BEO(;4M# P!)DPV#D[L!"/E !8 G;D'D9(0'>4M9OA M[78]GR6UU?O(C M*LD^5+*0&&^4Y!(Y'(Z>HKM:** "BBB@!:*** "BL_7=:3186NY 2B;BQC>X;)6-&8XZX4 M$G&<<\4 6**H:#K2:U"MW&"$?=@, &^5BIZ$CJ/6K],!:***0!1161;>)X[B M[DTP!O-B0,20-F"%/!SG/SCMZT :]%9'B?Q/'X=C%Q,&*LX7Y "/E/7': MM>@ HHJOJ%ZMC&]PV2L2,QQUPH).,XYXH L450T'6DUN%;N($(^[ 8 -\K%3 MT)'4>M7Z "EI*6@ HHHH&%%%% !1110(****!A161;>)XKB[DTP!O-B0,20- MF"%/!SG/SCMZUKT %+24M !1110 4444 %%%+Q'$;B$,%5ROS@ Y ![$\< MT ;%%%% !1110 4444 %%%% !15>_OX]/C:XF8*B#))_SR3T ')/ YKAD^*D MMX2UI92RQ XW#/7 )!"HX!&?[QXP>] 'H-%*=%8NK8*C:P M7&>#GD9!48Y';GJJ "BBB@ HK T?QO;ZQ/0 $D^P&3VI]% '$?#C29]T^IWBE9KE^ ZD,J MKZ;B6"DX 4XX13R,5V]%% !1110 4444 %%%% !1110 4444 %<1I.GRIK5S M<%&$30* Y4A"<0\!L8)X/Y&NWHH **** "BBBD(**Y^S\5_:;^72MF/)C#[] MVN@H **** "BBN?\%^*_\ A)H6N=GE[9"F-V[HJG.<+_>H M Z"BBB@ HHHH **** "BBN?\5^-(?#/E^9Y*NOE M;<^8%'WLXQAF_NTQF_1110 45@>"_%7_ DT+7.SR]LA3&[=T53G.%_O5OT M%%%% '#?V=-K.K?:)%(MK-?DWHP5F(Z@/C)#$G>H(PB^H-=S110 55U734U2 M)[:49212#TR,]",@C(/(.." :M44 <#X-FN?#DIT>>-W@5OW4R1-M&[YL$@8 MP2>3D[6R"2O*]]110 4444 %%%% !1165X=\21>($::#.Q)&3+#&2 #D#.<$ M$8S@^H% &K1110 445@>*O&">'O+1D>22;<(UC .67& >?N'E[=V[(V[<9W9 MZ8QSGIB@"6BN!;XHR7+,;.TDGB5MHD7< 2 ,\"-L=> 3G&"0,XKI/"GBN+Q) M%YT7#+@.A/S*?Z@]CW]B" ;5%%96D^)(M5EGMHL[K9@KDC"DG(P.ZD=B/_KC((-7Z "B MBB@ HHHH **** "BLKQ1KG]A6SWFW?Y>WY<[<[F"]<'USTJWI-]_:$,=SC;Y ML:/C.<;E!QGC.,T 6J**X'_A=-G_ ')O^^4_^.4 =]7-_$:T>[L)HHE+N?+P MJ LQQ(I/ YZ5B_\ "Z;/^Y-_WRG_ ,W2@#?HHHH **** "BBB@ H MHHH Q?%>NR:1%N@B>:5LA51&90?[S%1P!Z=6Z#N1E?#_ ,+-IJM?7!SYZUV6AZY%K<0N8#E6Z@ M_>4]U([$?_7&00: +]%+H\BV<,9GN&Y,<9.0,9YPK'..<8Z%/^ !T]%<-8_$XB5(;VW>V63(5Y"=N1CKN1<#GD M\XR,X&2.RO[^/3XVN)F"H@R2?\\D] !R3P.: )Z*\\/Q5FD4SQ64C0C<1)E@ MNU22!SS7::'KD6MQ"Y@.5;J#]Y3W4CL1_\ 7&00: *GBS4[C3(E MGM8O.82+O0 EMASG&.. 20..3TE9OB#Q##H,7VBN!Z MD5R?_"TWC_?26Y''%:] !1110!Q.E:?*FM7-P481- H#E2$)Q#P&Q@G@_D:[:LBY\3Q6]W' MIA#>;*A8$ ;, ,>3G.?D/;TK7H ***@U"]6PB>X;)6)&8XZX4$G&<<\4 3T5 M0T'6DUN%;N($(^[ < -\K%3T)'4>M7Z "BBB@ HHHH **** "BBB@ HHK(N? M$\5O=QZ80WFRH6! &S #'DYSGY#V]* ->BBB@#AO'7AZ6WE36[(9N(A4J,]5H>JG5(A,T;Q,>&212K CKU R/0CK['(!KVM)HD+ M7K?Q)<+D+*BL,]<, 1G&>>: )Z*** "BLBY\ M3Q6]W'IA#>;*A8$ ;, ,>3G.?D/;TK7H **** "N=\7:Y=:08I+: SHQ82!0 M2XX&S&W.!UR=I'&."17144 >?2^-]1OU,$%C)'*X(5Y"=J]\_.B+G'3)QG'! MZ'I_!WA[^P+9+4D%QDNRC +,<_4X&%!/) ' Z#:HH **** "BBB@ HHHH ** M** *&N:J=+B,RQO*PX5(U+,2>G0' ]2>GN< \KX%\/2W$KZW>C%Q-D*A3;L M^7.&&0<+@?[/4L6..YK(UKQ/%I$L%O(&+7+[5V@$ Y4)XKB[DTP!O- MB0,20-F"%/!SG/SCMZT :]%%% "T444A!1110 4444 %%%% !116/XG\3Q>' M(A<3!BK.%^0 G)!/Y''% &K+*(E+G.%!/ +'CT !)/L M!D]JXOX<:3/NGU.\4K-1BJ_P#PNFS_ +DW_?*? M_'*ZKP]XG@\0(9;=L[<;E(PRDC."/ZC()!P3B@#5HHK/U[6DT2%KN4$HFW(0 M M\S!1U('4^M &A15?3[U;^)+AX;)6)&8XZX4$G&<<\57T'6DUN%;N($(^[ < -\K%3T)'4>M &A1110 M 45E>*-<_L*V>\V[_+V_+G;GE6M)OO[0ACN<;?-C1\9SCY''% &Q16?H.M)K<*W<0(1 M]V X ;Y6*GH2.H]:T* "N#\$:-)>W=QK-RC*S.5B65-CA<#G:5X(7:H(//S@ MYZUWE% !1110 4444 %%%% !17.^+O'$'AI0),M*X)5%QGO@DG[JYXSR>N < M'&!+\4+BU'F3V,L<0(W.2W ) S\T:C// )&3QF@#T&BL_0=:36X5NX@0C[L! MP WRL5/0D=1ZUH4 %%%% !116?KVM)HD+7 ML>*5L;+^U%0LI2-@I.TXD*@9(#8(W>]:6DWW]H0QW.-OFQH^,YQN4'&>,XS0 M!:HHK \.>*O[9FN;;9M^RR;,[MV[YG&<8&/N^_6@#?KAO%.G3:]?V]KM/V6# M$DC,C>66!SM.["OD *,9(W-G."!W-% !1110(**** "BBB@8445@>(_%7]C3 M6UMLW?:I-F=VW;\R#.,'/WO;I0(WZ2EI* "BN)U;XIPQ2"VLXVN9>E2T %%97BC7/["M MWO-N_P O;\N=N=S!>N#ZYZ5;TJ^_M"&.YQM\V-'QG.-R@XSQG&:!%JBBB@ H MHHH 2BBB@ HHHH **** "BJ^H7HL8WN&R5C1F..N%!)QG'/%0:%K2:U"MW&" M$?=@, &^5BIZ$CJ/6@"_16!9^*OM-]+I6S'DQA]^[.GO6_0 4 M444 %%%9&B^)X]7DGMXPP:V?:VX G+#C!/'RGKCM0!K4444P"BBB@ HK L_ M%7VF^ETK9CR8P^_=G.0AQMQQ]_U/3WK?I %%%% !1113 *2EI* "BBB@ HHH MH **** "BBB@ I*R=&\31ZO)/;QA@UL^UMP !.6'&">/E/7':C6?$T>D206\ M@8M,(M!VQD&2:3[D:PSZ GCN2>@.#B M#PUXJGU:0Q36LD"A"VY]V"00-O*+SSGKVH Z6BBN+O\ XKVMC(]NR2EHW93A M4QE20<9<<<4 =I17':;\5K*]<1G?'GHTB@+DD#&59L=>IP !R178T %%%9%M MXECN+J330&\R) Q) V8.T\'.<_,.WK3$:]%%% !161;>)8[BZDTT!O,B0,20 M-F#M/!SG/S#MZUKT )1110 45A>'O%']L37-OLV_99-N=V[=\SC.,#'W??K6 M[0 4444 %%%% !1110 4E+24 %%%% !1110 4444 %%%% !24M)0 4444 %% M%% !2TE% "T4E% "T4E% "T444 %+244 +1244 +1244 MR^9 MQ]H@'E]]V F>G3_5MUQT]QGNZ2&59M+BFD6Y9 98_NOCYAD,,9ZXPQX/&3G& M:Y/5/%%UJUP^G:8 /*R))I!PK ]!D$=05Y4D\D !=U=M7 _!N("UD? W&8@G M') 1"!GT&3CZGUH$-GUC4_"^)[TI/;LP#F,89.V>%03 M2OLKVRB5+G)P0VYA\A4+C!!(;N#SCCM6WXMB$MG9VO^JTC_KO)_Z4+0,W=3N]:LXVU!VC5$P6A50QP" >BL<8^8G?P,G(Q@6( MM?U'Q.!)8JL$.!^\EP2S#AE'#?+DX!V\[3\P.5'4^*?^/2X_ZX2_^@&LSX9_ M\@^'_MI_Z,>@"#P3XEFNI)M-O,&X@).X CI M>RZ;:PI(552N<@C*JQ+'1]T5)\8_\ CT3_ *[K_P"@/7>4 8G@[Q&/$%NMS@!P2K@9 MP&'IGL00>^,XR2#5#P7XO;5[62]N=JB)W!V!L;516)P2QSR>GY5F_!S_ (]' M_P"N[?\ H"5'\)K5;NQEA<91YG5AR,AHT!&1STH 98WVK>)$%Y;/%!$Q8*IP MQ(#$9)*/SV_ASC.T=]SPWJ-Y:K,-3 "P*&$BCAERY8_+QP%& %#8QD9-8=GH M&J>%QY=HT=Q#GY4?Y2-W);!*X&1C Z'G!!!/. #)L;[5O$B"]MGB@B8L%4X8D!B,DE'Y[?PYQG:,\]!X M1GOLR07X&8]NR10,.&+Y.1QQ@8&%(!&X9-<]9Z!JGA<>7:-'<0Y^5'^4C=R6 MP2N!D8P'(YSMR3C<\(^,SK+-:SQF*YC4%E((!&!EAD KR1P>Q&">< #O /B: M3Q# UQ,%#+*5^0$# 53W)YYK'/B6]\4.ZZ9MC@B('G2#[Q[@95N#G.-N0 "2 M-P6LWP+_ ,@B\_[;_P#HE:Z7X81!-/B( !8R$X'4[V&3ZG ^@ H S!XEO?" M[HNI[9()21YT8^Z>P.%7@8SC;D@D@G:5JYXF\97&EWL5C!$)1)&#MY#DDN.& MR0 -H))'3.2!R+'Q/B#Z?*2 2IC(R.A\Q1D>AP2/H2*YG3?^0AIO_7@G_HN6 M@#2OAK<0-V&BPH5C!&NX\8RO*DD]F M>Q!![XSC)(-;=<'\&_\ CS?_ *[M_P"@)0!WE>>:O ?$FK+928\FS0.5.#NR M%8]5/!+*"#QM!(()KT.N#^'G_'YJ/_7?_P!GEH VOB!-/%9R?9U#95A)N[1E M&W,/F'(XQU^AKC?!^I:K#:QI:01O"-^UF(!/SMG_ ):KWR.@KT#Q3_QYW'_7 M"7_T UE_#+_D'P_]M/\ T8] ',75_/9ZQYR,FK&C_\ (%D4<$@'J3R>!C&X% M5*D5UM<'I'A&_P#ML6HWDL3YE#*A9#R07)''!&.?OGCKDU?0IHM1@U*W7!;/2Y M%N(8MLB9P=[G&00>"Q'0U@>!O]$U#4+>3B1Y!(!URNYCG(XZ2+QUYZ<' !WM M4+G3T@9[V*(-<>6P&,*S\ A2W3DJ "<[>W&:OT4 <+H'AZZTC3Y_E+7MP7)^ M=5<%OE!\S<7'(Y)'!YK?\%Z$=$M([=@ ^-SX 'S-R02"%SGD =N*VZ M* /.]'@/AK5VLH\>3>(7"C VX#,.BC@%6 XVD$DD5Z+7!?$3_C\T[_KX_\ M9XJ[RD!0UV:>&%GM%#S#;M5N%/S#/\2]LGJ*Y"72M=0%A<1,0"0 ,@Y.1G!%8W5X8FV MKA8L^Y(8(8UR,]1NSZX H W_ 7XG?6EDCG4)<6\A215SMZG![CJ".&/3/0B MNCKSKX5VYMI[Z)F+LDJJ6/5B&E!8Y)Y/7J?K7HM,#C_$7C=M&OHK-E!A>+<= MJLTI8[PJJ <99E4#COU'42Z-K.I7LZ&6V6*U<9)+ R#Y,C/S Y+8XV @'!Z9 MK-UC_D.6O_7NW\IJZOQ+*8;6=U)#+!*00<$$(2"".A%(#DCXFOO%,CII>V." M(@>=*/O'N!E6X.F6]JQV MGR8&5L$X(0)(_$6FSW,8(_<3*RG^%A&21GN.00?0]CD Y/P=J6J MPVL:6D$;PC?M9B Q^=L_\M5[Y'05OZA\0)+"]FL3'YBQQ@Q+&K&5W*HVW()& M,%B3MX [G@W_ (8_\@Z'_MI_Z->LO1_^0[=?]>Z_RAH TM.U/5)C,9K>-%$4 MAB 8,2XQL1B).0>YPH^E9O\ 9NNS_O//A3=SLP#MSSMSY3=.GWC]3UKH?&?B M0>'K9KG +DA4!S@L?7'8 $]LXQD$BN6MO#^K:\%GN+DVZL&94C!5UW$84JNS MC'3"#Y@YX7^(]3QZ:_@G3GTW5KB"20RNMOR[9W'/E$=2Q MX!QU[5?T?_D.W7_7NO\ *&@8:UXPO]%LQ=7$4:3&X"!>6784+9^60\Y!'7IV M[UT_BGQ+'X=@-S(">=JJ/XF() SV'!)/H.,G /,?&?\ X\X_^OA?_0)*;\2H MA-=:2QND\J[AR64 [2N1R.3ZCN000RD@\=37G^JQ!-=MB 6@8G QD[9 MAD^IP /H * *^@>,]2\2QLEO%&K!B#,=PC4%3@!26)8'G(W 9&Y<'-$OB/4? M"LL?]HE);>5@#(J\)USRJJE CS^QO]7\3(+VV>*"%BP52 Q(5B,DE'Y[?PYQG:,\[7A^[U)([B*Z1 M6FB3,+ +(3OQD@A<9 XPI (+8SFL6R\/ZKX5'E6C1W$.?E1_E(WYG!/()VCD @<+G()R M3A0IW#!S0,SY;#7K4>:)HI=I!V *-W(R,F-./7Y@<=#G%%_XKGUW2FN;=%+D M.DX.<*H1M[+DKS@J0/FQG')!H3P-J5X3+<7S(Y/2'?LP #@-& ?8+[YR36; MX"_Y ]Y_V\?^B%H B\&ZEJT-I&EI!&\(W[68@,?G;/\ RU7OD=!73^)?%L[7 M TG3U#7!&7=P=D8(R#]1D')R.BX9C@6/AA_R#H/^VG_HUZX[2(-0OKV^-E,J M%9R'\WYL@,X0#*/PH!';C ^@!KW5SK/AY3>3M'<1)C>BC#! ,9^8# M.2I )&EXL\*8U6QC6(@8EF?E _7" YX('/RL1N M.,!CZ-7 ?!?_ (\Y/^OAO_0(Z )O"_B2ZM;QM(U$AI&7='(JX!^7)48501@' MG P589/&+_C#Q@^EO'8VJ>;=S8*J0=H7)Y/(]#W !9B . 1G&5(.!FF? MV/KO_/U#_P!\C_XS7,^)_#$OAS2Q;S%2S7H;Y"2,&(CN!SQ2 ZR:36=8 FA\ MNU3LDAWR$$ Y8E& YS@84CD,. :L>!?%L^H22Z?>J$N8 #P"-PX!)'*YR0<@ MX8,-HP,UV-<#HW_(=NO^O=?Y0TP.8L+_ %)=2FE2&,W9B ="1L"XCP0?,'/" M_P 1ZGCT].\,7-W<1%KZ-8Y=Y "$$;<#!X9^?'Q/?>*I'32]L<$1 \Z5?O'N "K<'.<;<@ $E=P6NL\5_P#'G<_]>\O_ M * :R/A9$J:?$0 "QD)P,9/F,,GU. !] !0!ECQ/?>%9$35-LD$I(\Z)?NGL M" J\#&<;<<>KOBG$K MZ=*2 2IC(R,X/F*,CT."1]"17,:W_P P3_ME_P"T*0&Q?1:Y> SQM%",-B$% M6?@G +,C*6(QSN"],A>:U? GBUO$$;>+ M=+CU76;:VF7=&]N<1R"#U% ':?\)79_P#/Q#_W]3_XJLKQ-X]BTV)6 MMB)Y96*1K&=ZEAC.2N>FX?*/F.0!C)(/^%7Z=_SQ_P#(DO\ \77,/X;M])UJ MUMX4 0Q%\$EOF EPWS$\C:"/0C(YH TOL>N_\?'FP_WO)P/KY>=G_ <[_P#@ M7>MWP7XM'B"-@ZE)X2%E0@C!Y&1GL<'@\J00>Q/15Y[H42Q:[=!0 /(!X&.6 M\DD_4DDGU/- $6@?$FZU>(K% );K>PP@*1(NS*L[,2,EL@#<,X/(.,V-:\8Z MAHEF+JXBC2CX+?\>1[($525AVAY" -PX*.=Q!VX^7D?=%,L/&.H>*HU6QC M6(@8EF?E _7" YX('/RL1N .,!CZ/7 ?!;_CSD_Z^&_] CI@2^%_$EU:WC:1 MJ)#2,NZ.15P#\N2HPB@C /.!@JPR>,=U7 :S_P AVU_Z]V_E-7?T <1\8(I' ML1N*\<\X/;(W_#OB*UU6-!;,OW 1&" Z@<8*#H!T].F" M016K+$LRE& *L""",@@\$$'J#7$:G\'K.YR8M\1VX 5MRYYPQ#Y)]P&' ['F M@#LC81F476T>:$*;N^TD-M]QD9&>G..IS8KS;PG=W7AR^&B7#>;%(I,;$\A5 M5MI&IH Z^N(U# M4)/&4C6-HQ6S0XGG7^/UBC/<'N>F/]G D'T[5X[6X2259)W$8B\K:I'S?O.2 MD8!*G@YR,<8.*Q]"CUC1(A;06D(5>I++N8]V)\[DG_ZPP !0!8\+V$>GZU<6 M\*A42V4 #Z0_F3U)/)/)YKT>O&;"_P!274II4AC-V8@'0D; N(\$'S!SPO\ M$>IX]/9J "BBH;NZ6T1IG.$12S'!. HR3@<]*!'':A;:U>RNT,D4,2NRH" 2 MR@G:Y^63D@^HZ?='>OIGB*_T2YCL=3V.EPQ"2IC.["X&% XR0O*@Y.=VT5GV M-YJOC0&6)Q;6Q8 8R&(#9)5@-Q(Z$@HI(QQ\V*&M^')M&O+#SKE[C?<+CS-W MR[7CSC+MUS[=*0SJO$7B*ZN[K^R-.V+(L>^223^'H0 "".A'9L[NV":KV@UK M398S.T<\+NJOL4?(&=06P%C;."?[P R6'&:G\2>"[B6Y_M/3Y1%,RA7#YVD M$9SA@> HV[<<;LYJDGC^\T>15U2W$<3D 219*KG=UPSACQT!# G!X%,#T*J M^H/(D3M" TH1B@/0L =H/(X)]Q]:GK#\:>)1X=MFN< N2%0'."Q]<=@ 3VSC M&02* .=_LW79_P!YY\*;N=F =N>=N?*;IT^\?J>M:'@KQ3/>22:=?*%N8%4_ M+_$I R3MRN>03@@'=PHP:Q[;P_JVOA9[BY-NK!F5(P5==Q&%*KLXQTW,S#H1 MDFJ_@C3GTW5[BWED,KK;\R/G<<^41U+'@''7M0 :+XPU7Q2A2V2./#$-,00H MX! 8MD\$' ;AAPO4O@\9ZAH\SZ7<(+BY<*860;5)8#K\J90[?RFH I:KJ^K^'U74;EHWA+C?"@'RA\ M\%@G '0-N;YL?>SSW5_XAALK8ZBQ)AV*P(!R0V-N <)\ M[$<98KG(;)1SR#C/R@XR% ()U?"_BFRQR>4K+\F0V"K@# C4=6H M ;:^-[_4+BXL;>"-S#*5#DLJ(HKZOX5 NKEH[B' M.&"@#;DCDD(A!/0'YE!ZC)&;OPY_X_-2_P"OC_V>6M7XH?\ (.G_ .V?_HU* M +NO^+X=(M1J!RZR!?+ !&XN-RCD?*,(1R.AX8CGL3ZUZG2 \Q\$33S M:OV."(@>=*OWCW !5N#G.-N M0 "2NX+5"]E:'4]2=20RV#D$'!!$<1!!'0BJ_@W3=6FM(WM)XTA._:K@%A\[ M9_Y9-WR>IH VH/$5_P"&I8XM3V203M@3)A0C' )P@P,9.0#@DACM*UJ^,/& M#Z6\=C:IYMW-@JI!VA@%>@UYY\4;5;NYT^%QE'F96&2,AFB!&1STH Z M[_A*[/\ Y^(?^_J?XTV[\6VMO#)=B172$ MY3!S\QPHPIZL>!G ]2!DUF_\ M"K]._P">/_D27_XNN8^)/AR#P_98M%,8FGC#X=SN"K(0#N8\ \_7!["F!=M; MK6?$*B\@:.WB?.Q'&6*YR&R4<\@XS\H.,A0""=3POXHG,[:5J"A;A5RCKPLB MC@D ]2>6^48QN!52I%4/[&UW_GZA_P"^1_\ &:-'\'W_ -NBU*]ECD\I67Y, MAL%7 &!&HZM2 YKX>W5_+;/:6"!0,AJVKKQ% MJ?A)EEU#9/;NR@M'M# D-PN AS@9.5(. P)-6_@M_QYR?\ 7PW_ *!'6K\4 M/^0=/_VS_P#1J4 ,\;^,6\.2VR_+Y4SL)"P8D*I3)&TCG#'L>W%16_B'4K^5 M&CM1':LX#&8@2[=^&;;O4J=O.-K>Q8$5SNM_\P3_ +9?^T*]3I@XDBB8*>$R^ MTMU8< $X^;\ZYJ72M>12PN(F(!. JY..PS"!D^Y ]34NH>+6\/Z?9K"H>>>* M%44ACT1HW9]< 4@ M-+1/&LMY:W3RJJW5D)-ZC)3*ABIZGC*D$!CTSD BL_3/']YK$"_9+<23D-O; ME(4(? 7+,-S%2"0&&,@\\@8OA2V:UBU>)F+LB.I8]6($P+')/)Z]3]:[+X7_ M /(.@_[:?^C7H S[3QE=V-S;VFH1H@N5/**WRON*JNX,X;.%SC&-XS@#GM+N MZ6T1IG.$12S'!. HR3@<]*Y/XIZ6US:?:8\B6V=9%*C+@9PV&'*@9#$_[//J M,_QAXL&J6$*6^?-U JBJ&*XPP$B[B "-WR'. 0V>F:8&[X%\13>(8GNY5"(9 M"(U"MG:.Y8G#>, R/*&QCD$*,>QSGUTKBX?XASK%&,:?;R LS @R,.PZ$9!( !!4'2<,/"\NOJJ1SM"H#A@H)#A\#! =>!@]<]37,?".Q M_L^:^ML[O*D1,XQG:THSCG&<5Z37 _#G_C\U+_KX_P#9Y: &?%257ELK:4@0 M23YD!.!A2BY+<$ *[=QUSV&/0:R/%7AJ/Q% ;:0D<[E8?PL 0#CN.2".X/&# M@CF+7PWK-L1$MXAB#'YG7?)M)Z_,A)..Q?';.* &>$(ETK5;RPB $3(LG3&# M\I"C& %'FD 8Z <]<^@UYMX!TPQ:E=.)3*(8UC9Y"=[.=N>O8&-AUX&,$CFO M2: .8\3IJ5Q*(;$QQQ; QD?!.[)!3!#\8P?N_P# NU<[J&I:QX8'VNY:.>$8 MWA=JX!90.0J')S@8# 5ESR 00=RD ;N I)* M[@=N<8OBWP9=Z=9O<3WDDH4)NC)S_[=_\ T0U>ITP..\"^+9]0DET^]4)

&+<[5^7);HW_(=NO\ KW7^ M4-'P;_>VTL[6)Y[D^M(#%\90ZM9VDB7;1S0OLW,F R;7 M7'\,>=QP.C=.W?T/PI_QYVW_ %[Q?^@"LOXH?\@Z?_MG_P"C4K4\*?\ 'G;? M]>\7_H I@:M>:?"/6[>PM'2:6-&,['#NJG&Q!G!(XXKTNO)_ACX-M-;MGFN( M][B9E!WNO 5#C"L!U)H ]#_X2NS_ .?B'_OZG^-8?B7Q;.UP-)T]0UP1EW<' M9&",@_49!R3M'<1)C>B##! ,9^8#.2I )%+X M@ZVMTVFW\"F0%V=5'WB0T1V?+N^;(VD#.#Q5V[\.:W=HT+W,)1U*L, 9##!& M1#GI65JFBOHATFTE(+I(K% );K>PP@*1(NS*L[,2,EL@#<,X/(.,V-:\ M87^B68NKB*-)C<@CKT[=Z/@M_QYR?]?#?^@1T?&G_CSC_Z M^%_] DI =]7,6'B>6XU*;3"%\J*(," =^2(SRE=/7 Z-_R';K_KW7 M^4-,"_KT.K7DS):-'#"FW:SX+/N49_ADQM.1T7KW[9$FOZEX5D1]1:.6VD=5 M9U &W.[. JJV0!N.5((& 0347]OZCXPDE33V6*VC+*)""-V< ?,5+!L?,-H4 MJ#R<[2<7X@^$[C2+=99KN2=3*%VONP"58[N7;GC'3OUI =IXC\29"%@NU9$;+,,8 MV@C/(.*BUG_D.VO_ %[M_*:N^I@8?@OQ*/$5LMS@!P2K@9P&'IGL00>^,XR2 M#5+Q3XLDL+BWTZV4-+.PW%E9@J$XW;5*YZ$GYN ISU!&/X5E&@:E<:65((/U! (]#S3J*8!7GGPJ"R37TT0Q"\P\LA2JX#2 M$ # Q@$<=@1Q4_C#Q+)JLAT/3P'E<%97_@1>C#///.&/;[HRY^7JO#N@QZ% MEK&!\H&X@8W-CYF/)Y/U.!@#@"@#D_A5&E]]IU3;B2>X<8.#M7A\ X!Y+<]C M@<#%6OBUIJ7-BT[#YX&4J>,_,P0C.,X(.<#'('I5?X.1-#:2HP(9;EP01@@A M$!!!Z$5I_%#_ )!T_P#VS_\ 1J4@-_2;[^T(8[G&WS8T?&!S0!ROQ9EC2P.,C MO@X7BR/S;;3-+E4KYS0ACT9=JJA&".O[SOT(Z&K&F6\GCRY6_G0+8VY81(XR M7)X)/J,@$]5XV -\YJU\18F-WISX.T7(!.. 2\9 SZG!Q]#Z4@.ZBB6%0B@! M5 & . !T K@_!\::5JE[81+A&5)!T 7&"5 QF7CT YZUWU<'HL3'7 M+M\':($!.. 2L1 SZG!Q]#Z4P-#QCX(E\1L"+EHHM@4QA2R$ABVXC>HSR.W8 M8Y86W1 MR+DE22,\9'H,'(((!!Z@X%KX;UE@();Q%CVE2R+ODQC Y**2??<#WSF@ ^%G M^AO>Z>O^KM[@[2?O')9.3TZ1CH!SG\.^KS[X3V@W7ERCEXI)]JLQ)=MFYMS9 M Y8.#ZYSD"O0: "N=\9^+1X?C4(I>>8E8D )R>!DX[#(X'+$@#N1T5<#KW[[ M6[2)^46%F"GE0V)3N /&@H /L>N_\?'FP_P![R<#Z^7G9_P !SO\ M^!=ZU9_&#Z/8B]ODVS%F3RT! +!F"C)+8!"YW9(QR,Y /4UY]\2XEFN].1@" MK3D$$9!!>($$'J#0 16^NZDHN!+% ' /EE>5^H,;D$]<%B1G!QT&QX/\8/JC MR6-TGE7<.2R@':5R.1R?4=R""&4D'CJ:\^U6)4UZV( !:!B<#&3MF&3ZG ^ M@ H K^'_ !IJ7B:-DMXHU8,09CN$:@J< *2Q+ \Y&X#(W+@YHE\2:EX4EC_M M$I+;RL 9$7A.N>513G'S8*G:KXT!EB<6UL6 &,AB V258#<2.A(**2,XWW"X\S=\NUX\XR[=<^W2D!VU_XGEM]2ATP!?*EB+$D' M?D"0\'.,?(.WK5+Q1XTN-*O8K""(2B6,-MY5R27'#9( &T$DKP,Y('(JZS_R M';7_ *]V_E-1K/\ R';7_KW;^4U #+]==B4W@:+"A6,$:[CQC*\J23USA\GG M:>@K8T?QD=4T^345 $L4=H>-2WL<$8/!X!QG(S74UY9X"_Y ]Y_V\?\ MHA: .LTCQ/+>::=38+YHBF; !V9C+@<9)Q\HSS6'I/B35?$\(:WCCA^]F9R= MI(88"*0Q'&020P/."I&*E\-?\@)O^O>Z_G)6K\+_ /D'0?\ ;3_T:] &/I?B M>^T6[CT_4MKI.<)*JXY( &U0"-W!!4$%MQ.W&=CQAXP?2WCL;5/-NYL%5(. MT+D\GD>A[@ LQ '.5\1O^/S3?\ KX_]GBHTW]_KMQO^;R[<;-W.W(BSMST^ M\W3U/J: &16VO6RB,$A4&5SGA\<<$]#M?#[Q/+XCMVN)@H9 M92OR @8"J>Y//-=/7 _!;_CSD_Z^&_\ 0(Z8'?5R&O0ZM>3,EHT<,*;=K/@L M^Y1G^&3&TY'1>O?MU]>:?V_J/C"25-/98K:,LHD((W9P!\Q4L&Q\PVA2H/)S MM) )9-?U+PK(CZBT3M'<1)C>B##! M ,9^8#.2I )#OAU$IOM1? W"<@''(!DD)&?0X&?H/2N_EB692C %6!!!&00> M""#U!I %*B0'O($8$ CDFC4U"^:8H6 MP0=F9"@/&0]K_..@ MM4U?Q%$D MMNL=LI53N" 1GH0S U+X5\5745T=(U$#S-I,(+R_&KHZ1(9 ME5Q"I(VM'^]PQ^?KC<>J].GKWWA6\O[GS/[0B2/&W9Y9!SG.[.'?IQZ=>]8& ML_\ (=M?^O=OY35WU, KSZU\;W^H7%Q8V\,;F*4J')9410Y7+\_,2!P%(/!( M#8Q7H-<#\.?^/S4O^OC_ -GEH I:GJ^K^%0+JY:.XASA@H V\CDD(A!/0'YE M!ZC)&=?Q-X^.E_8YD $-W\SF1265/W9R IZ@,?[W/3WW_%?_ !YW/_7O+_Z M:\LM?]5HW_7Q+_Z4)2 [>W\0ZE?RHT=J([5G 8S$"7;OPS;=ZE3MYQM;V+ B MJ^J^*KK5[A]-TL >3D2S2#Y58'H,@CJ"O*DGD@ +NKN:\^^"L2BTD? W&<@G M') 1"!GT&3CZGUI@-N-:U3PKMN+XI<6[, YB&&0= >%0:]>U71DO[=[+ 5'C*#Y057C"D+P/E.".F M,#&*0%JTNENT69#E'4,IP1D,,@X//2N;TSQ9)JE_+8Q*/L]NIWOM8L7!QMSD M!><]0V=A(X.1B^"?& L-.E\\'S+#*LK[MQR3Y:\J=O/R8YV[/[S1Y%75+<1Q.0!)%DJN=W7#.&/'0$, "<'@4_X MC?\ 'YIO_7Q_[/%2 U_#%_J5Q*5OH8XXMA(*$$[LC XD?C&>WXUD?8]=O?WO MFPP[O^6> =N..NR3KC/WCU[=!U^OZPNC027;\B-?_: QMH U?#'B6[M[K^R=2"^8R,T M;KCY\%NH7C! )&0A 7D$FN0L+_4EU*:5(8S=F(!T)&P+B/!!\P<\+_$>IX]+ M]AHLND:S;133-.QB=MSYR 4E&WEFXXSU[]*V-&_Y#MU_U[K_ "AH OMXNGT6 MT:[U*,)+YFU$C.0V5!7D,X'(;))X Z$X!S8;?7=2 N!+% ' /EE>5^H,;D$] M<%B1G!QT#?BJTK36,4+;7:8[<_=WAHPC$8(."?0\$^M2_P!C:[_S]0_]\C_X MS0!:TGQS+/#=)<1B.\LXW8H?NL I*D#=G'3."0000WS #+TOQ!J_BF-7MUC@ M09S*PX8@D84,'.,$?PGE3\P^[3%\)7EA]MU&\DC=I;*924SG.T8XV*,87'%= M%\+_ /D'0?\ ;3_T:] '.Z?XYU!6DTOR1->QN<-C:A0U+PI+%)J,B2V\K%6*+PG3YLK&ISC) YW ,,9P1:T;_D.W7_7NO\H:/C3_ M ,>5^H,;D$]<%B1G!QT#?BJTK36,4+;7:8[<_=WAHPC$8(."?0\$^ MM2_V-KO_ #]0_P#?(_\ C- &QX.\5R:JTEI=((KJ _,HZ$'HR@DG XR>1RI! MPV!SOA_QIJ?B:-DMXHU8,09CN$:@J< *2Q+ \Y&X#(W+@YK2\)>$KRPO)-1O M)(W:6+:2F;=S8*J0=H7)Y/(]#W !9B .<>6WUW35- MP98IP@)\L+RWT C0DCK@,"<8&>A-*B5]>N20"5@4C(S@[81D>AP2/H2*]!I M<)K/BR37M,>ZLD!R'297_@7RV,A!RN2,@@C.0?NYR!A>#=3U:&TC2T@C> ;] MK.0&/SMG_EJO?(Z"G>'XEA76D4 *HD & // Z 5UOPO_ .0=!_VT_P#1 MKTP.JK@/C3_QYQ_]?"_^@25WU<#\:?\ CSC_ .OA?_0)* ._KSCP181G4[JZ MM%'V0(4#+]S>3&S*OJ,ACQ\H&,<%#0Y M)/-BEC+Q';@J?F)&"> =K< MS@C&6H EM/B--)/6!\RG<^U\[9&/ (QR/QJ+X<_P#' MYJ7_ %\?^SRUJ_%#_D'3_P#;/_T:E !K/C,Z7I\>HL 998X]J\[2\BAO3R!C.3FLB6PUYU,PFB4D%O+ 7(SSL!,9&1TY8CU;O6B_AE?$>F6]JQVGR8& M5L$[2$'.,C.02.3WSU%98O-:\/J%=$NHUVY9,M)C(7;QM8GC.XHW7))P0 "[ MX@U&^FTQI&B43,)5F4\!8P)%9ER_)P 1RVX/.#D!_P +_P#D M'0?]M/\ T:] %?Q+XMG:X&DZ>H:X(R[N#LC!&0?J,@Y.1T7#,<#-NKK6?#RF M\G:.XB3&]$&&"YR6R$0\ 8S\P&E=_+$LRE& *L""",@@\$$'J#0!Q?C?5X]8TB2[BSLD$9&1@C$J@@CU!!'IZ M$CFNB\*?\>=M_P!>\7_H"UY7HW_("NO^OA?YPUZ)90SS:9"EHP29E89(R&:($9'/2I?[&UW_GZA_[Y'_QF MCXC?\?FF_P#7Q_[/%0 _X;3-I4EQH!RZ$GJC8Z 9"CD-C.,@UC^*_ M^*IN;GO;Z;;R_C*5;_=889?]I?W?HU:'Q.MI=*E@URW^]#\C C:M:5HKZ5I,_G$F6:&>63<22&>,\'(!S@#=G)W9YI 5?#^J3:5HD M=U;@,\>\E65F!7SF#?=92, [B>0 #QW'::!K"ZS!'=IP)%SCG@CAER0,X((S MCG&1Q6%\-(EFTR%& *L)001D$&1P00>H-9'P\U0:']JTNX8_Z(SR!F#X *MP&8I)[6_UQLJ]RDQC.0",Y6('H36AK/_ "';7_KW M;^4U %VP\1Z@\@GN;=8;((SNQ;=(JB,MR P.?0KNU6[1H7&4=2K#)&0PP1D<]*\]LO#VJ^% M5\JS:.XAS\J/\I&[DM@LN!D$8#D-CK3-:3QF&YB4%D((!&!EAD KR1\I[$8+XS@X'H*X75/A$;%?M&G32+,@) 9@"< M\8#J$VG&1SD'(!(&32 [>[N(/"]LTN-D,63M09Y=LX [99N!P!GL!QR%K=:S MXA47D#1V\3YV(XRQ7.0V2CGD'&?E!QD* 03@>(O%@ M.Y@JOA^&P-Q3IM'^Z*V+#Q/+<:E-IA"^5%$&! ._)$9Y.<8^<]O2L?6?^0[: M_P#7NW\IJ-&_Y#MU_P!>Z_RAH [+6[UK"WEN%P6BB=AGIE5)&<8XXKF/^$UF M_LK^U]J>;Z8;9_KO+Z;L]/?K^5;_ (L_X\[G_KWE_P#0#7 ?\R[_ )_Y^:8& M[XUO6O\ 1C<-@-+%;L<=,L\9.,YXYK,T>35M4MX!:[+:*.%%!D(9I,#&[!1B MHP 0,#KD%@1BWXE_Y 2_]>]K_..NI\*?\>=M_P!>\7_H I H6]E&&>6=LR,0$CQ(XW$$< MGYB0.O&=K $5N_$;_C\TW_KX_P#9XJ/AS_Q^:E_U\?\ L\M %34-2UCPP/M= MRT<\(QO"[5P"R@N& (SC//-4O%?_ M !YW/_7O+_Z :ROA?_R#H/\ MI_Z->F!U5-+C2KV*P@B$HEC# M;>5!P<<-Y((^A! M(/J.* .@@UW5/%+&:Q"P6P+;6D );&!SD/SU^Z HY4L2*Q];^WQWEC%J&QME MPNR2/'SY>,MD#'W>!]U?QZUZ-X/B6*RMPH 'D1G@8Y902?J223ZGFN8^(W_' MYIO_ %\?^SQ4 =_7*_$K7&T>S9XR5DD945EQD$Y).>WRJ0".02,8ZCJJX7XQ M6K360=1D1S(S3I=C'ON'51&AR55%X!)R">%/?@ LQ '.9+!KFF@W!EBF" GRPO+?0" M-"2.N P)Q@9Z'-U*.\O-8N$LI0DB0IS)RH3;&2H!5\?,<]!W]>=7^Q]=_P"? MJ'_OD?\ QF@ \4^($U_1Y+M!C=Y89<@E6$J9!Q^8Z$@@X&:W--U>/1]-ANY< M[([:$G R3E% 'J20/3U('-23@^HR ?J : +5I>:SXA'VJ QV\+#*!P#N!)P>4=LXQSA0 M1@J.:L:/XJOX+Z+2KU8_G5CO4'@R".H*\J2>2 M NZJMQK6J>%=MQ?%+BW9@',0PR#H#PJ#DGN""1MRI()P/ EKJE]"\MG.B(9 MFW>:-S%RJDMDQN>01WZULZIX3UG5(VMIKB%HWQD8QG!!'(A!ZB@#8\;>-9-$ M-L;95E6X+<#)+ ;-H0J>K;N#ANW'K4OHM;O 9XVBA&&Q""K/P3@%F1E+$8YW M!>F0O-4/%5D;&32+=L%HW13CIE3"#C...*]*H$FE,4>LE20?/0<''#3N"/H02#ZCBMK1-*UEX(FAN(EB,2% 5&0I4;0?W)Y M]S]:!FIHWB6[TRY33-3"DRC]W,F K'D[3]T9Y"@ YQP=P:NVKSH^#-3OI[> MXNYHG6WE5AC(.-REL8C7).T=:]%H$7_T UE_# M#_D'0?\ ;3_T:] '+76H3V6LW)M8O-E>%5 +;5'[N,[B3Q@$8QD9S@')%7-8 MN-:T4-?.\4L:DEHT7("G//W5;:O^\2.IR,FK&C_\AVZ_Z]U_E#74^*_^/.Y_ MZ]Y?_0#0 VQULZK9B]ME!=XF*J>F\ C82=O 88SP#UZ5S']FZ[/^\\^%-W.S M .W/.W/E-TZ?>/U/6J^A^)1X=T:*YP"Y+J@.<%C*_7'8 $]LXQD$BBV\/ZMK MP6>XN3;JP9E2,%77<1A2J[.,=-S,PZ$9)H T/#?BN[N//L+A%%];Q;D QA_E M&-V#M!R5SA@#NX P:Y'PI?ZE%/=M;0QO*TN9@Q "MN?@?O%XR6[MT'/KK^"= M.?3=6N())#*ZV_+MG<<^41U+'@''7M5_X=?\?FI?]?'_ +/+0!UVA33S0J]V MH28[MRKRH^8X_B;M@]35^BJ&O:PNC027;\B-?O?-AAW?\L\ [<<==DG7&?O'KVZ"?PSXDN[>Y_LG40OF,A:-UQ\^"W4+ MQ@@$C(4@+R"36786NK>+%6X>86T#G($8*O@+@, ,,58_WG_V@,;:JV.BR:1K M%M%-,T[&)VW/G(!24;>6;CC/7OTI#-?1_P#D.W7_ %[K_*&G7^OWVN7,UEIK M1QI;$!Y'&26Y!7!5N,@C[I^[G=@@%NC_ /(=NO\ KW7^4-.U'P?>:;)\X8C!QDY!+-NYRFW. 0"< BQHC:K97"0WA26"3.70#Y"%<@3RP8X) (')JO\/(@;W47P-PG(!QR 9)"1GT.!GZ#TH 9= M7.L>'U-Y.T=Q$F-Z*,,%SDMD(AX QGY@,Y*D#([;1M7CU>%+J+.R09&1@C!P M01Z@@CT]"1S5J6(3 HP!5@001D$'@@@]0:X3X,_\>;_]?#?^@1T =]7GY\37 MWBF1TTO;'!$0/.E'WCW RK<'.<;<@ $D;@M==XEE,-K.ZDAE@E((.""$)!!' M0BL7X71!-/B( !8R$X&,GS&&3ZG ^@ H BT675;*>."[\N6&0MNE0@R".H*\J2>2 NZNXK@/ M@Q$!:R/@;C.03CD@(A SZ#)Q]3ZT ,GUG4_"V+B^*7%NS .8AAD[ \*@Y)[@ M@D8RI()O^,/',FE?97M4$J763@AMS#Y"H7&""P;N#SCCM6YXOB$MG86O^JT?_ *^)?_2A* .LOHM;O 9XVBA&&Q$"K/P3@%F5 ME+$8YW!>G"\U?\(>-O[4AFDN@(Y+4MYH"MPH!.<')!X((R3E>V0*ZNO/? UJ MMWI)'<172*TT29A8 !9"=^,D$+C('&%(!&[&.-9+ MJ5EE')V@2*HVD.1G:V>2>?RJ#X=_\?FH_P#7Q_[/+1\1/^/S3O\ KX_]GBH MH?&::?8D>T?9MRG?_%YF)!MQNZ;>?N]>_:M[0M2U6:94NX(TA.[:?]?"_^@25WE ',^ /$TGB*!KB8*&64K\@(& JGN3SS1X_ M\32>'8%N(0I9I0OS@D8*L>Q'/%9'P:_X\W_Z^&_] CH^,O\ QYI_U\+_ .@2 M4= */QEFGV)'M'V;-(3OVJP!8?.V?\ EDW?)ZFK M6L^"M6UI!#<3PN@8,!]WD C.5B!Z$T :5_KU[KES-9Z1QDEN05P5 M;C.1]W^'.[! ,^B-JME<)#=E)8),Y= /D(5R!P$(R0,DJ1T ()J#4?"%WIMS M)J&FR*/-)9XGSAB,'&3D$LV[G*;3RP8X) (')H [BLCQ,]V(PMB%,C.%)?HJD'+\GJ#CLW^Z:UJY#QOXKFT^2 M/3[)0US.">03M'(! X7.03DG"A3N&#FF!0DL-=MAY@FBEVD'8 HW^,XR2#7.)X(U&\)DN+YD2I! M**VYB3MV@G&/ESD#=GKW5<'H_P#R'+K_ *]U_E#3 KZO<:SHH:]=XI(U)+1H MN0%.>?NJVU?]XGN"PAU.W0 S2!2LF6 P'W?=*YY7@]QV!Z=O7@ M_P#S"/\ M_\ _:-(#T.[\4W]^=^GVP:$'AYCMWC (95+(0ISP>""#U!KRWP/X:7Q% MIDELQVG[265L$X(1.<9&<@D6 N1GG8"8R,CIRQ M'JW>M2_\1W.GZ" 1GH0Q!IWAKQ7=077]D:@H,A!*2*,;L M;FR>@*D# ( ((PPSG'2^%O\ CSM_^N$7_H KE_B'_P ?FG?]=_\ V>*@"75/ M%%UJUP^G:8 /*R))I!PK ]!D$=05Y4D\D !=U59]9U/POB>]*3V[, YC&&3L M#PJ#DGN""1C*D@G!\#6VIWT+RVDZ(AF;=YGS,7*J2V3&YY!'?K6SJ?A36-4C M:WFN(6C?&1C'0@CD1 ]12 Z/Q9XP71HD:(>;+<<0JN6#9Q\V1U'(P!RV0!W( MQOL>N?Z_S8?[WE8'U\O.S_@.=_\ P+O5-[,V^IZ?9RX80VJ\=4W*D@+ 'OE0 M0< \#T%>D4P/(_B'J%[=6L/VJ)43?\Q'!$BM*H4 N3M* '."#U#8XKK]"U+5 M9IE2[@C2$[MS*02/E./^6K=\#H:H?&3_ (\T_P"NZ_\ H#UWE '-> ?$TGB* M!KB8*&64K\@(& JGN3SS2>/O$LGAZ!;B$*6:4+\X)&"K'L1SQ63\&_\ CS?_ M *[M_P"@)1\9/^/-/^NZ_P#H#T= -'Q;XDFMYHM-L@IN)PQR^<(N#\WH3P3W MQMQM.163<1ZYI@\_?'.%SF-5&2,'G 2,G'8**R9?%^HZ 0;^ /".#)%UX(&\D$@9SP"$R3QC!% M 'H-4M8U9-(A>ZESLC&3@9)R< >I) ]/4@> ME<3\8_\ CT3_ *[K_P"@/0!%;7.L>(%%W"T=O$V=B,,DKG(;)1SR#C/R@XR% M .3H^'/%MBB$("* %4 8 X M'0"N#^(40%[I[X&XS $XY($D9 SZ#)Q]3ZT 8FO7E\-61UB0S*KB%21AH_WF M&/S]<9/5>G3U[OPO>7UQO^WQ)'C;LV$'.<[LX=^G'IUK!U?_ )#EK_UP;^4U M=Y0@"N$^'O\ Q]ZC_P!=_P#V>6N[KR;1?!L/B2[OO.9QY4[8V%1]YY,YRK?W M:&!TOQ5BAFM0C &X9U$( )^VHM5\2R>%(["W<*%9%6;<" MQ4((PV-IZC)]?:L[6/AJ-#0ZA93.LENK/\^#G:,D J!CC/!!#=#@9J+6]9_M ME]*N\8+S'(Q@;EDC5LE=-7!Z1_R'+K_K@O\ M*&@"*+6]1\4-))I[QQ6\4A5689+\#GYD8CC!Z+C=CYB.-?PQ)J,$S6U]M>/8 MS+*@')!0;?E"X')ZJ"2#@D"LA/"E_P"&G>33G1X68MY+Y'4D #-I+F;^SKV(PW!!*X!V-@MG&/3M&\63Z-:-=ZC&%E\S:B1GALJ"O(9P.0V23P M!T)P#0TC_D.77_7!?Y0TSXCQ":ZT]& *M,001D$%X@00>H- "Q0:WJ(%P)(H M0X!\LKROU!C<@GK@L2,X..@UO"7BU]3=[*Z3R[J')90#M*Y'(Y/J.Y!!#*2# MQT]<#JD037+<@ %H6)P.IVRC)]3@ ?0 4 /^'O\ Q]ZC_P!=_P#V>6N[KA/A M[_Q]ZC_UW_\ 9Y:UO$MCJ-Q(&L9HXX]@!#@$[LG)YC;C&._X4(#I:*YKPU8Z MC;R%KZ:.2/80 @ .[(P>(UXQGO\ A724Q"T4E% "T4E% "TE%% !1110 44E M% "T4E% "T4E% "TE%% !1110 4444P"BBBD 4444 %%%%,!:*2EI %%%% ! M1110 4444 ,C(."P!8%3RI'0YXYR,FW\9ZC8#R;B MR>21=:C=7_C)19"W-M"6'FO+DG .1@,J$\CMGG )49S/XF\/&VETV&W1FCMY>2J MYP-T9W,5& 3@DGC)R:[ZBE8#.\21&:UG102S0R@ #))*$ #J36=\/;5[2QB MCD4JXWY5@5(S(Q'!YZ5T5%,1QFEV$B:Q<7!1A&T*@.5.PG$7 ;&">#^1HTNP MD36+BX*,(VA4!RIV$XBX#8P3P?R-=G12&<9\5["2^M42%&=A,IPBECC8XS@ M\L6[9@@$#($@)]PWMC(-'A[1 M[R5KG5YE$=S-!MB1<#G8,$JV<'*KPQX.[Q9W!ZP[M MF" 0,@2 GW#>V,@U:\%:/<2W$NKWBB.29%547CY<+DE3D@_*O!.0=V0.*[2B M@#B?A;I3V]I)#<1E=\SY61",J40=&'(/(]*H6EK>>!F>*"(W-K(V5V_ZQ6([ M[58]%P3C:>""I)6O1:* /.KNTO/'+)%/$;:UC;XKMZ* "N+^%&GR6-JZ3(R,9V. M'4J<;$&<$#CBNTHH *\^L+@:#K$MNWR17JAEY!!<\Y))R,MO '[:ZAF7YOF&=@8-@GG##CC@@FNV\+75U-%MO MH]DJ8&X,A#_[6%)P?4=.XZX&S0!Q>E:?(FL7-P481M H#E3L)Q%P&Q@G@_D: MZ/Q)$9K6=%!+-!* ,DDH0 .I-:-% '$Z#X5_M32DL+@&-_G(W+\RMYC%3A MAGIUZ$J2,C.:H:?K^I>'%%E-:F=8U"H\6<;5) R55@> , A6 Y8$FO1J* .- MT+7M1U:=6>W\FU#'=NXDXC.!\V"06(.50>F>#GLJ** "BBB@#B]=OM2TBXDF M@C$]JYC;;DEUP K*H!W DC/"LHSNQ]ZJ5QXTU*_'DVUD\3) X/]Y44' MTW$CM@YKT&B@#DK+PL=$TR:S7YY7AF+; 3N=D(P!UZ848 SC. 37.>&/%%YH M=NEG]AF?R]WS8=<[F+=/+/KZUZA10!Q>G^.[JYD2)K&5%=U4L=^%!(!8YB' MZ]1]:/&G@N:\F74[%@ES&.1PN[:#@YQRQ^Z0WRE< D <]K10!P$?CV_@'ERV M$C.I()CWA#@GI\C\>X8@]1Q6EX4FU&_F^TWJB*(0X5%XRS,&W%=S$$ 8.X@C M. .6KK:* "BBL;Q3=74,6VQCWROD;BR!4_VL,1D^@Z=STP0#E[^X&O:Q%;K\ M\5DK,W( #CG((.3AM@([$$8QG/H-I!P2TE+0!Q6JZ?(^LVUP$8QK P+A24!Q+P6Q@'D?F*[.6(3 HP M!5@001D$'@@@]0:=10!YM;6=]X%=H[>(W-H[[@%'[P$J1CY02#P,G:5( QM) M(J>;QAJFI?NK6S,3;6RTN?8 J7$:Y&>AW9], UZ%12 X#Q!IEWH%X=4L4,D4 MH'G1+CDYP?E SDYR& 8AMQ;Y20:NM>)=1UF"5$MC;QK$YE>;.=NTDA=RKR0" M. W4ZG+%0@"*-2[G.%4%F.+G)X'/2NAD- M[9V-J+- TR)$'23 ^41$$'<5((;'0@Y'ID5TFGV0L8TMUR5C15&>N% SC'/ M%6* //!X]U&91&EBXE.T;F#^7G(R<%5P#[OQU).*U?"O@YM/T]["0[9+A9-_ M1@ID7:,8QG SSUS@XQ7744 >6Z)KVH>&H/[/-D[M'NVNH9E^?YAG8)YP MPXXX()K>[7):$_.BL(CDQD*K$#. ,>O!SDY-&O6UUH&H-JL$) MGCGC5651\P. ,?+N/_+,'<5QSMZX->A4M 'E_C"YNO$MB&-M(CK=C$81V?8( MC\Q^4$C<3S@#H.O)Z[QOX2'B6#R@0LJ'QDDE0 ,\9.UN^?D1USCK@XSG@=!<\(>%9EGDU>_Q]IDR%10I"#@9 MR,\X&!@_=SN)+'':44 <3\)=/DL;5TF1D8SL<.I4XV(,X(''%'Q:T^2^M42% M&=A.IPBECC8XS@ \XZXZ\>M6J* //T M\V,@U:\$:- MU^SMWDN"VT @XPI123D=@P'\0PU#PS!_9QLG=H]VUU#,OS_,,[ P;!/.&'''!!-:OB/PYF2P VDY*@D [BW]X,0.^HH&>?2^/\ 4)QY<-A(KL0 9-Y0 M9(Z_(G'N6 '4\"H/'%E>:EIL0FC+7/V@LZ1+OP/WNW[F[@ J,Y/N%9FGCU>PQ]ICP&1@H#CD9R<9M^]MDV[L==OEYQGMNSCC/>J7C&UU#5;$"YB/G?:P0D*[\((B,_(7. M-V>ISD^F!7J-% !7$Z3I\J:U#^1KMJ*!'GFO6UU MX?U%M6@A,\<\:HRH/F!P!CY=Q_Y9@[BN.=O7!KJ?"NLS:O&\T\)@(D(5'#!M MH53G+ 9R2>0 .W4$G:HH&-EB692C %6!!!&00>""#U!KSBSM+SP&TD4$)NK2 M1MR[?]8K$=]JL>BX)V[3\I!4DK7I-% 'F]Y:7GCQHXIX3:VD;;FW?ZQF [;E M4]&P#MVCYB2Q 6K_ (XTEY+G3O)C)CAFY\M"510T6,X&% ]A@>U=U12 *XC MP%I\MK=Z@\B,JR3Y0LI 8;Y3D$CD6Q"W5L=R9"_-@A@I)'4$97/RY)!&#D= M910!P'_"=ZA_J/L#^;]W=EO+W=-WW<;<\_?QC^+O6EX$\(OI >\N2&NKD[GP M%^7)+%00.I)RV/ER ,#)ZVB@#B/A'I\MA:.DR,C&=CAU*G&Q!G! XXH^+FG MRW]HB0HSL)U.$4L<;'&< 'CFNWHH$%<1\(]/EL+1TF1D8SL<.I4XV(,X(''% M=O10!Q&K:?*^M6UP$8Q+ P+A24!Q-P6Q@'D?F*[>BB@#"\7Q79B22PP98Y58 MJ2 '7#*5.2 1R#R1TR#N KFHO'^H0#RYK"1G4D$Q[PAP3T^1^/<,0>HX->A4 M4 <+X4T2ZU*Y_MG4%".L86*,#! (Y8C)(X9AALG).0NU:[JBB@ HHHH XC2= M/E36KFX*,(F@4!RI"$XAX#8P3P?R-'Q2\5RZ#%$MNQ261R<[58;4'S#Y@>26 M7''8\COV]<;J'AR;5M3CN95(M;5 4.\$,X.[.T,"IR1G@@[ #P1@ Z?2H9(8 MD2=M\H4;VX +=\851C/ X!QC/.:?J%DM_&]NV0LJ,IQUPP(.,YYYJQ24 >7Z M%JFH^#T-A):M.BDE&BR0 6.?F5&R">0" PSSP0 :W9ZCJ-W9W-S$ BS@A(@7 M\L"122[@$9(QSG&!G"G->H44#.+U[7]2TBX9DM_/M2R[=G,G,8R/D)( 8$Y9 M#Z9Y&,743>^.FCM9+8V]LDB,[.2'X# X+*,Y!P $.&P20#7IU% !7-_$'PVW MB"U,,?\ K$8.@R "1D$$D=P3CISC) S7244 >?6'C+4]HM6LF:[7):$_.BL(B28R%5B!G &/7@YRGRV%HZ3(R,9V.'4J<;$&<$#CBC5=/E?6K:X",8E@8%PI* XFX+8P#R M/S%=M10!S?Q&M'N[":*)2[GR\*@+,<2*3P.>E,/AE=9TV*QF!1O(BY*_,CJ@ MYP>A'0C@X)&1FNGHH \VT_Q#J7AM18S6AG6-0J/#NQM4D#)56!X P"%8 98$ MG-:N@Z_J6KW"L]OY%J&;=OXDXC.!\Y!(+$'*H/3/!SVE% '$^ M/EM;O4'D1 ME62?*EE(##?*<@D[L)HHE+N?+PJ LQQ(I/ YZ5TE% '#:YX M0;6],@A"XN(88BH;"G(0!D)(R,CMQ\P7) %5;7QMJ4:BV>R=IQE?,^81ELX# M'"[<>I#A3R05'3T.B@#S;PCI-T^I7$U_'_K;I;;6=]X$=HK>(W-G(^X!1^\!*D8^4$@\#)VE2 ,;2Q%>ET4 >>3>,=5U/\ M=6MF8FVMEI<^P!4N(UR,]#NSZ8!J?QUX=N(;B+6;!0TT0(=<#D '!V\%B5)4 MX.[&T*.,CO** .!_X2_4M6_<6]F87/62647G6T_+Q* &4Y.T*%!. M6XV@X7(81_"#SM!*C.;' MQ'\.-%I\-E:1LXBE3A%W-@(X+$*.I)R3CDGWKT&B@ KB=*T^5-:N;@HPB:!0 M'*D(3B'@-C!/!_(UVU% !7$^/=/ENKO3WC1F6.?+%5)"C?$-' M%/";6TC;DT4 <3X]T^6ZN]/>-&98Y\L54 MD*-\1R2!P.#U]#7;444 >;7=I>>$KR:\MH3/;73;F5>6W'=R'QPH4$ $ G*J<#()!(KTZB@#S[7O"MQ? MV5E+;@BZM$B(5L+_ IGAQC9E7!5AF1B.#STKI** &RQ+,I1@"K @@C((/!!!Z@UY)\//# M[27SQ2L9(M.:0)DC:'+E00A)QG!;CHP!)Z9]0UIY4@D-N"9MC! -OWB,*?G( M7 /)SV'0]#D?#[PVWA^U$,G^L=B[C((!. "!V &>O.<$C% '24444 ,]>_2N)\%ZW>>&86MOL,TFZ0OG:Z]548QY M;?W:]=HH R/%VKG2+2:Y&0RIA2 #AF.U3@\8#$$^W8]*S?AS?7.I6WVNZDWF M5CM&U5 525_A5>20>Y&,8PI)Y)Y/-;L8?QG M9RP7$3VQ=MH#9+?+M=6PRKD9X([X/(/3J:* /-M-\3:AX>06$MF\YA^59(MP M4J -O(C8' [\''##<#G5\#^'I_-DUF].)[A<",# 5?EQD=]NE>NT4 8NI:S-!9B]CA+2E8F,.&+?,R[UX&<@$\XX(R1VKF_ M^$OU+5OW%O9F%SUDG+;5!XR-R(,@D'^+@'Y37?44 8?@OPT/#MLMMD%R2SD9 MP6/IGL .V<9P"36Y110!YM=VEYX2O)KRVA,]M=-N95Y;<=S?PJ67:Q.#@KM M(!.[!$7BJ[U+Q%:.1;^3#\F4.YYW(?'"A00 0"1N548L,0L#D 9&#P?>O2:** .)TK3Y4UJYN"C")H% MV,$\'\C65-I]WX,NY;BT@,UK<$$HF,@X) 5GRV%HZ3(R,9V.'4J<;$&<$#CBNVHH *X'Q'X?2^/]0G'EPV$BNQ !DWE!DCK\ MB<>Y8 =3P*H>*[74+H6$[1%KJ.65F55RBGS$,8)4X"X Y+= GRV%HZ3(R,9V.'4J<;$&<$#CBM+X@^&V\06IAC M_P!8C!T&0 2,@@DCN"<=.<9(&:Z2B@#SZP\9:GM%JUDS3@,OF$E(RRY^8_*% MQQV#9%Y@*Q(&DF MR4X=L#@#D8^4@G#*>#7K%% '$ZKI\KZU;7 1C$L# N%)0'$W!;& >1^8KMJ* M* /.?C%;-;+!J,3%)4#@\ \\ #)Q61KGAZ?6=1@E8%;6U 8-E.7SNX RV"0H.X 85L8R">Q MH *YCXB7EU;6N+)6,DCA28U+.JD,21MZ'@#/;/&#@CIZ* /)_"FMS^&XO)BT MZ8LV"[G?N8_]^N .P[>Y))['PQXLN-7E,4UI) H0MN?=@D$#;RB\\YZ]NE=/ M10!YY?V%UX0NI+ZUC-Q!=L3)&H^=6^9ARJDXR3@X(P2K#.UC7NX;SQ[(EO/" MUK:Q$,^\'>S<@;2RKS@D=,+DELG:M>ET4 2/J+O@Z2::UCFN7WR2J'SA0 &Y4 *J]L9SGG/.,5D>,_#DWB&YM MH"I^R1DO(V\8)_N[-P;.!@,,XWG'0Y[&@ KRGX@F[O[P1/!+-9PE2$B5U5R4 M!)+A6RI6L?DR6,CS("ID"OL+#(# M;50@CUVM@]B 1C=\!^%Y-'62XN6S<73!Y ,;0M>AT4 4- T==&@CM$Y$:XSSR3RS8)., MDDXSQG XKC? /B6Y\1W4\ID/V6(DJA5 WSD[ 2%)P%!S\V'?[ M4@;_ %C?/)_O-C(ZD?* %XX. M,]Z -^N3\=^$7U<)>6Q"W5L=R9"_-@A@I)'4$97/RY)!&#D=910!P/\ PG>H M?ZC[ _F_=W9;R]W3=]W&W//W\8_B[U:U7PI-XIL52[Q'=JSL#A2H)9L)E=WR ME<="3P"=Q&#VE% 'GT7C?4;!1!/8R22H &>,G:W?/R(ZYQUP<9SP.@N^#_"D MRSR:O?X^TR9"HH4A!P,Y&><# P?NYW$ECCM** .)^$>GRV%HZ3(R,9V.'4J< M;$&<$#CBCXN:?+?VB)"C.PG4X12QQL<9P >.:[:B@#EOB1X=DUVU\J'F1)%< M+P-W52,D@# ;/X8[UF:?XEN_$!73[BTDA29'660AP,&-L[=R *2V,9+>G)YK MO** /+]"U34?!Z&PDM6G122C19( +'/S*C9!/(! 89YX( -;L]1U&[L[FYB M19P0D0+^6!(I)=P",D8YSC SA3FO4** .)U73Y7UJVN C&)8&!<*2@.)N"V, M \C\Q1JNGROK5MTL(8I5*./,RK@JPS(Q'!YZ5TE% '$^/=/ENKO3WC1F6.?+%5)"C?$.S5BPC!^8\9+$L3CL,DX'.!W/6D!I5Y?IJWW@622WCMVN+61V:/ M9RPZ3^.DU+7X$D>#9%Y@*Q(&DFR4X=L#@#D8^ M4@G#*>#7K%%% !7 ZS_R';7_ *]V_E-73^)[F[MX@UC&LDN\ AR -N#D\LG. M<=_PKG?"OA6ZENCJ^HD>9M(CC4YV9R.QV@!")H< $C +%?=MN>,MOYPP) JW_B+4?$D;6,-HT'FC#R2D[0AX;[R+SSVW M-C.%SR/1J* .&\0>%/[+TF2PMU,C_(3M3+.WF*6.%&>G3J0H R<9I_B#3Y9= M%6W5&,OD6XV!27RICR-N,Y&#GTKMJ* ,WPS$T-I;HP(98(@01@@A ""#T(KF M]5T^5]:MK@(QB6!@7"DH#B;@MC /(_,5VU% '!^-]-N;.\@UFVC,WDH59 .< M9(XP=Q)$AZ*=N,G(XK:\)^(KC66D,]NUNJ!-H<-EB=VXY95X&!P!QW/(QT5% M !7D6B:Q=:5>7TMM!Y\?VAO,4'YQ\\@3;C)ZDYPK<#MUKUVN0\%Z#-IMS?33 M+M2>;=&=RG(W2'. 21PPZXH P]1NM1\:#[%]G-M;L4\QI02W!+<;@N1P.%&< M@98*:N^+=">*;3(H4=X[>106"EL*K1 %B!@<+UX'!KOJ* "O/)]&N?!MQ)>6 M47G6T_+Q* &4Y.T*%!. 6XV@X7(81_"#SM!*C.=K78I=.@CT?3D<.ZA1*%VI&H^\[.%QN;!Z?-DEA\VT M-U]% '-_\()!]B_LO QM^_MY\S&/-QG.<]L]/ESMXH\&WMPJFQO%?SH./-() MCD7/RL'P 2 0"#\QZGG<%Z2B@#R+Q?X?:75191L1'>^6\B1D(,*3O)YPQ&QG MR1U/0GKZW%$L*A% "J , < #H!7(>$_#TZ7ESJMT"K2DK&I*$[,@C<$R M,@*H'S9X;.>">QH *XO7M?U+2+AF2W\^U++MV^.FCM9+8V]LDB,[.2'X# X+*,Y!P $.&P20#6U\2-%GNOL][:KODM M)"^S&19E7!5AF1B.# MSTKI** .)TK3Y4UJYN"C")H% V,$\'\C1\7-/EO[1$A1G83J<(I8 MXV.,X /'-=M10!SOCCPBOB6#R@0LJ'AT4 9$D5PO W=5(R2 ,!L_ACO74T4 <7X M?\97FHS16\UH\2MGS)&5]O",> 5&W+ 8RQXXY)S7:444 <7XP\*3-/'J]AC[ M3'@,C!0''(SDXYP<')^[C:05&:4OC?4;]3!!8R1RN"%>0G:O?/SHBYQTR<9Q MP>A]!HH XO3?!G]@:=<6Z_/-+#(6*KR6,9 1>,D#MGDDDX&<#0^'-H]I80Q2 MJ4<>9E7!5AF1B.#STKI** "N)^+FGRW]HB0HSL)U.$4L<;'&< 'CFNVHH X' M_A8UY_T#IO\ Q_\ ^-58\-:!=WMV=6U%51XTV1(A'''+95CQRPP2Q)8] %KM MJ* .)\!:?+:W>H/(C*LD^5+*0&&^4Y!(Y'(Z>HK2^(UH]W8311*7<^7A4!9C MB12>!STKI** .3D-[9V-J+- TR)$'23"_*(B"#N*D$-CH0%/!K:?I[V$AVR7"R;^C!3(NT8Q MC. !GGKG!QBN;T/7M0\,P?V<;)W:/=M=0S+\_P PSL#!L$\X8<<<$$UZG10! MP>O>';C1;LZS8*)-X(FAP 2, L5]VVYXRV_G# D"K?\ B+4?$D;6,-HT'FC# MR2D[0AX;[R+SSVW-C.%SR/1J* .&U_PG_9>DR6%NID?Y"=J99V\Q2QPHSTZ= M2% &3C-=/X9B:&TMT8$,L$0((P00@!!!Z$5IT4""N(\>Z?+=7>GO&C,L<^7* MJ2%&^(Y) X'!Z^AKMZ* "LSQ-$TUI<(H)9H)0 !DDE" !U)K3HH YKX:HVI3 K#"FV')3)R"IX7/R\L>2&Y7T(" Z6PT>*Q@6R508E M3;A@#D8P W:*WB-S9R/N 4?O 2I&/E!(/ R=I4@#&T ML17IE%,#SN?QCJNI_NK6S,3;6RTN?8 J7$:Y&>AW9], U=U;3Y7UJVN C&)8 M&!<*2@.)N"V, \C\Q7;T4 5-6\SR9/(_UOEOLZ?>VG;][CKCKQZUQ">.M2LR M8KBP9W!ZP[]F" 0,A9 3[AO;&0:]"HH XCP/HUS+<3:Q>H(Y9T151>/EPN25 M)8@_*N 3D'=D#BNWHHH&<1K]_J>CW$D\$0GM7,;;H#R+:R>*1L_/)N*@8/]]44'N-Q([8.:]$HI <7;_#I8]-;3&(, MK9??SCS>Q&02 I( )7/ )-8^C^*=1T&);&:RDE,0"ADSC: -HRB.I('&0? M8\@D^F44 >4V#W7(',I9I&&!\B+M!RP)&2I!Z!@PJ'^R9O[!^ MS>6_F_W-C;_^/C=]W&>G/3IS7I5)3 XGQ!I\LNBK;JC&7R+<; I+Y4QY&W&< MC!SZ5F:3XLU#1H8[:6Q=]L:!3'N'RA0 & 5\-QR#@_[([^DT4 <-X=T.YU6\ M_MJ]'E;%VPQ#&0K*?O'KP&/!PQ;.0H 4X6F3W^@W=Y<16K20R3L6R&5B-[[" MGJ/FR<*W'IUKU:B@#S;4KN_\:J+$6YMH2P\UY3>.DU+7X$D>#9%Y@*Q(&DFR4X=L#@#D8^4@G#*>#71 M:KI\KZS;7 1C$L# N%)0'$W!;& >1^8KMZ* "O/OASX<:73YK*ZC9!+*_#KM M;!1 & 8=01D''!'M7H-% CR[0M3U'P@AL)+5IT4DHT62 "QS\RHV03R 0&&> M>" (M3CU'5[NSN[B$I$LZE412Q1=Z,6 MVE&4D4@],C/0C((R#R#C@@&K5% 'F6GP:EX'_"W M#+G@'))JU-XPU34_W5K9F)MK9:7/L 5+B-V*U9O# M7]L:9'9.-L@MXMNX8*NJ#&<@D<\-QG!(KJ:KZ@DCQNL)"RE&"$] Q!VD\'@' MV/TH \^TWQ=J6D(+6YLY)G3C>I8Y& 1EE1PQ'<@_7Y@2:5@]W)K%L]\%65HG M(1,850DH X)Y)!;J>O4=!JQ:KKJ *;>)B !DLN3CN<3 9/L /05J^%/#MS%. M^J7S@SRIM"(<'!JKI]UJ/@L?8O(-S;J6\MH@0W)#<[0V!R>&&[:ZAF7Y_F&=@8-@GG##CC M@@FO4J* .)TK3Y$UFYN"C")H% )8C-:SHH)9H)0 !D MDE" !U)K2HH \WB\(RZIHT=IM*SQLSJC_(21(_!W#C*L<=.<9(&:GL?&.IX M%JUDS3@,OF$E(RRY^8_*%QQV@44 >>^$M,NX=4GGNUR6A/SHK"( MY,9"JQ S@#'KP7,T=NUQ#=/N!3.0 ME44 9OAW4)-1@6>>,Q.Q?*$$%0'8*#G!SM YP,]0 .*;XHT7^VK:6TS@NO!S M@;E(9<\'C(&>,XSCFM2BF!YQH7B34='1-/ELWD:/:JNIVKMP-H+!63CH6R!C M[W()+++3[^75;>ZO$'^J/,2L8T!20;"V"-VXG/S'DC!QBO2J*0'$Z5I\B:S< MW!1A&T"@.5(0G$7 ;&">#^1J*\\3ZGI,KJ]J9H2\GEF/._;ORI)3> -IP 5! M/KD'/=T4 >=6MO>>+;N"ZN(#!;VKEEW9#EL(N-% MNSK%@HDW@B:+ !(P"Q7W;;GC+;^<,"0.[I* /.[_ ,0ZCXCC:QAM&@\P89Y2 M=H0\-]Y%YY[;CC.!GD=AX9\/IH$"VJ<[BX)V[3\I!4DK M7H]% ''Z+X@U#5YXV:V,%L"V_>?G)"-C[VT[B]1][&16;/HUSX.N)+RRC M\ZVGY>)<:C=W_C-18BW-M"6'FO+DG .1 M@,J$\CMGG )49S/XG\.FUETV&WC9H[>7YBJYP \1W,5& 3@DGC)R:] HH *\ M_P##.GW-M)JCHC*\CL82RX#-F4J06&TC)'MR,\5Z!24P. 3QQJ-F3%<6+.X/ M6'=LP0"!D"0$^X;VQD&K7@G1KF6XEU>]01R3(BJB\?+A;?Z7X1N[F:.W:XANGW IG(.2W\(? &\CD#=C(Q@BGZU]IUI].NGA=6 M%PY=0C?(HE3;NR./E&!NZJ1DD M8#9_#'>JN@>,;S498K>6T>)3G?(ROMX1CP"HVY8#&2>..2SEATY)520=N 05 )&5X!S7\<)J6O0)(\&R+S 5B0&2;E.' M; X Y&/E()PP/!KU:BD!R_Q&\/2:Y:^5#S(DBN%X&[JI&20!@-G\,=ZI:+XK MNM7DCM+BS:-'#"5W5]A&QLC#* S8');CCDG-=K13 \VM[.^\"NT=O$;FT=] MP"C]X"5(Q\H)!X&3M*D 8VDD5/-XOU34OW5K9F)MK9:7/L 5+B- -IP 5!/KD'-6UM[OQ9=PW5Q M 8(+5RR[LARWRG'S#)!8#G:HQD9W"O0Z* "N(\=:)8,,\I.T(>&^\B\\]LG&<#/(UY-&N/#=I%;Z:HDD6 M3+[PJAPRMN)R5[[<8.0 !D@'/6TE 'GX\>:C,HC2Q<2G:-S!_+SD9."JX'U? MCJ2<55O_ XV@Z++#)_K'9'<9! )D0 @=@!GKSG!(Q7I58/CK3)-4LY;>%= MTC[,#('1U)Y) Z"@#E=%\87VFP11-9M*OE)L:(M@IM 7.U9/FXR>0>1\H[W_ M SH=UJ=T-8OP(V1-L<:C'!4\D9) ^8\$[MQ.< 'JM MFM+:&%QATAC5AP< M%5 (R..M7Z //+O1KKPA/)=V$8EMYR"\8'S+ANBA>V,D5WU%%@.+\2>$Y]6A@NU(6_MT1N0GS, & M*DXQD,"5_AR2,8.17_X3C4/]1]@?S?N[LMY>[IG[N-N>?OXQ_%WKO** .&\2 M:#>:_IRI*H%TLI9:2WC@:XMG=F39RW;DE5)!VX!!4 D9 M7@'-?QNFI:[ DCP;(O,!6) 9)N4X=L#@#D8^4@G# \&O5**+ >6'B#4/#J+8S6C3>6,*\1.TH.%^ZC<\=\'&,C/)M:'X M?N-9NAK%^HCV "&+ ) Y*EO==V><-OYPH ![FBE89Q>J6$CZQ;W 1C&L+ N% M.P'$O!;& >1^8KM**2F M>6Z;J5UX>NKQUM)95GF8@A7485W(((1L@[J]1HI M >>W^MZEXC1K6&U,"N-KM,3T?CC<%XQG=A6.#Q@XR:[X9:P?3+>!&=+>7YV5 M6(&7C9F/7:":GO=,D\1&59)LJ64@,-\AR"1R.1T]:[2BB@!**** M"BBB@ HHHH **** "BBB@!****8!1112 **** "BBB@ HHHI@)1110 4M)2T M@"BBB@ HHHI@%%%%(!:*2B@!:*2EH **** ..^(7C&;PWY7DJA\W?G>&/W=N M,89?6MOPMKPURW2Y&-Q&' [,.&&,G [C)SM()ZUS7Q"_X^]._P"N_P#[/%1X M6_XIN^ET@_ZJ;][#^7*]ST4C+$?/\ Q>WAR-&BVF21R '#$;5' MS'@CD$KW[]/31\(:R^LVL=W( '?=D*"!\KLHZDGH/6N+EC.OR7VJ-@QV\,T, M.""#A&RP*D9&"3R"/GX/RU:T:SEN=%46[,LJAV4HS*QVRL2/DY)*Y '0G'U M!Z%16)X,UPZU:QW#$%\;7P0?F7@D@ 8+<-C' ([WCLELQ_=11L/X21N.01D5VMGD"RQ.0Q.X9+ #:N=J\'@@@8>&_!L?BZ$7]W/(\K,P(5EPN&.%P0V.NX 8 ## [ MGK/"7A9_#QDC\TR0MM\M6SE.7+#'3G(R1C)SP.* .CKD?%?BFXCE&FZ>@>X* M%F)P0@P<=2 &Z'YN.5&&W<==7G'B6Z?PGJ/]J%"\%P@1B!TP%! .?O?(&&< MC('0L!@BU)8ZY;#S!-%+M(.P!1NY&1DQIQZ_,#CHL[3/B38W^T>9Y;-GY905QC/5N4&<09P"!M#E:/Q#NGM+&:2-BKC9AE)4C,B@\CGI0 M!=\2W-U;QAK%%DDW@$.<#;@Y/++SG'?\*R?B7KLVC6R36[;',RJ3M5N"KG&& M!'4"L;QGJLUOI=K,DCK(_D[F5V#',3$Y(.3D\GWJU\8_^/1/^NZ_^@/0!W=+ M7"R?#+^U3Y]_/)),0 3'M1 !\H!4\ YY 7.<[0'[PZ-/(9(VB#0 ME@<\ <#EMJ@*PP3CY0#2\&Z[-J-S>PRMN2";:@VJ,#=(,9 !/"CKFNMK MRC0M#FUF[OX$E,4)G(E"@%W!D?"@GH,;LG/?!5@35S6?AX?#L;7^GS2+)"I9 M@Q4[E!!/(VC )((8-@#'J >ET5F^'-6&KV\5UQF1 6P" &'# \X# C^IZU MI4""N+U#5=821UAMXFC#L$)89*Y.TG]Z.2/8?2NTHH&>:0^--6FG:Q6"$S1K MN9?0';SGS];VA:EJLTRI=P1I"=VYE()'RG'_+5N^!T-4-(_P"0Y=?] M<%_E#7>4 :X;>XF90=JKP%0XPH ZDUUU>1?#OPY-K5NZ&=H[7 MS6#)%@.S% &RV.%P5X^8'G@<&K&O:"W@%HK^TD$!ZK17)>.-8G5HM,LR!/=;LMNP451R?49&?FZ_*=H+8Q0_X5'#_ *WS MYO/^]YFY?O\ 7?C&[[W/WL_[6>:8'>45R7P^UN6\6:RN#NFM)-A?LPR0#D\D MY4\D#(P3DYKK: "BO--$O;_4+J]MK>3"K#D@8)"]>X .WHKSZU^&!U91<:E+(UPV2 M0K+A03D)RK#@D_=PHS@# R9?#TTOAR^_L:20RPRQ[H2W+)M!PI)(P,(1@9&0 MI 7+"@#O*6O-7AF\>SRQ^88[*!]F(\D28;.<_=)(&6=Q,FW;O7=C=E@J\ILQC<>H/X4 =UK-S=Q20+;1J\;/B8L<%5RO(^9>< M;NQZ#CUUZ\XU;59H_P"R,2./.\OS,.PWY\G.[GYNIZYZGUJUXXO6O[RWT?S# M%%*I:1E8 MNW*$[==I Y()894X (!WM'8%N(0I9I0OS@D8*L>Q'/ M%8=Q\(DMAYME/)',N=K,PQT(QE I7.>3SQG@U5^,NG/L2Z\P^7N5/*YV[L2- MOZXSCCIG'?M0!Z917):%X,N=.F6>2\DE1=V4;=M.5('61AP3GIVKF?!$FH:] M;M$DQ1/-8-,[&27E!\B@] .I.0?F!4Y!! /4Z*YJV\*SQ6DED;J1I'<,)CNW MJ!M^4?.3CY3_ !#J>/7F=2^&>FV68WN3'(5ROF2Q#KD [2JDC(]1G&,B@#TR MN9\*>)I-7GN[>0*%MI=J[002-SCG)//RCICO61X$U&75(KO3FF+M"S*D^"NX'<>H ( %-GQ,6."JY7D?,O."W8]!QZZ]>=:\)]$DTVT,\CEIV#MN9= MX,L9 8;CD -CDGBM+QYXAFB>+2K/B>YZM\V44G&1@'&<'+#)4*3C)! !V=%< M%_PJ&'_6^?-Y_P![S-R_?Z[\8W?>Y^]G_:SS4&C^)YQ!>:;B45YGX6\,S^*;5)+RYD,+;]L:'YCA^KNP.[E3@$ M''!!'(IJZ;)X&OK>*&1GMKI]OELW0G:I)XVY!*D$ $@;3@9N5E9F&=^,9()Y^]DC^+O5W7_#TZ:8T#W#;X!*[. M"Q,B 2$(V6!P5(R"6 QCDM;5>4> M#O!ESJ5K'/'>R1(V_"+NVC#L#TD4Z;> M_O4Q\@EC=GRZ\?+C@=2"&!QR!6_\14?5]/CU!7,:"-':($E6\TQX!.0/D/(R M#^% ';:)>F^@BN&P&DB1CCIEE!.,YXYJ[7GGA3P9<[+>[^VR>7MB?ROFV[C45Y MEK?A)O!,?]I6$SCRV7S$E(*N"=HX4*#@MW['*D$GN!AA@$ 'IM%>5>*/ I\,P_VK;S2&XB=6=W(YW':Q VDY+, M,AF(*D@Y[Z5IX$;Q2BW^H3NQE4.B185(PXS@;@W;;G '(.2QYH ]#HKA_A=J M$NV?39CN:SDV!LY&,LNT9 . 4.">Q P *I?99O'L\H:0I80NT8$3@^8RD'= MGD$=&R00!@*"=S4 >BT5YEK?A)O!,?\ :5A,X\ME\Q)2"K@G:.%"@X+=^QRI M!'-CQYK4]P=/>SD:,W)RN6*CY_*V;P,@@;N1@CKUH ]%I:X.^^%*ZD#+&^ [VXU"*[TN:0F6!F03;BS#?N7()PQVLI( M).>0.,"@#7\*>)Y=7GN[>0*%MI=J[002-SCG)//RCICO73UXUX4\*3W\]W%' M=R1-#+M9EW9D.YQN.''/!/)/4\^OJN@Z<^FPK;RR&5UW9=L[CEB1U+'@''7M M0!H45E>*;=Y[698BZR"-BIB)#[E^8 8YY(P0.2"15#P+KO\ :%C'9?#[Q7-=7CI.Q\N\5Y(59F?&UV^5><*,!P< M@9VC&.,[.O7(_A_%K M$LEW=SR"( %5#!4C 4!SEMPP=N3@+COFN.U&*#P:T=[IUUYB^8@DA$B,6 #$ MDE>,8X&4.TG(.<4 >Q4M3SQG@T >B445B^,/$/]@6SW0 +C 1 M6. 68X^IP,L0.2 >1U !M5R&I:]-#JUO8*V(9(2S+M7D@2\YQG^$=#VK%T_X M8MK:B\U*:1I9%!VC"E 26VG<#Z_= 4*<@9ZU2L-!;0]9MK!CM@<\ 4 >K45P.L//XLO'TR)_+M+; F:-OFF<'*G&".<@ ])HKSG5O'$^JV]K;VF%N+ MX$,1G*;3L9@!N(4D,0W)"J3][E;'_"GX?];Y\WVC[WF;E^_UWXQN^]S][/\ MM9YH T/B=KTVB6R36[;',RJ3M5N"KG&&!'4"NNKR_P"(VGRZ=ID,$\AE=;DY M*0Q.VW$B9W## GH5/(&.O>@"_17 MF.I?##3;+,;W)CD*Y7S98AUR =I521D>HSC&14OACQ!++::A;-*9&M%EV3;L ML05?:01D\%=P.X]0 < 4@/2:*\T\,6NH^([2,?:##%AQYF3)-(1)G.<@JH^Z M,,#P<@J1B[KMQ=:7';Z';R^9=7'F;IG;#JH);/)8C@D!LDX4[1NQ@ [ZBN!_ MX4_#_K?/F^T?>\S73RREB2Q92N2,G*]6)I@=Y7(^-->FTVYL886VI/-MD&U3D;HQC)!(X8],5S^D^"Y M?&2C4=1E<+)N,<2?*%!( (W @ @= #N&UBQ)-4-;\)_\([>6,:2N\37"[$DY MV8>,M@CCYB<\*/?/6D!Z[116+XQ\0_V!;/= N,!%8X!9CCZG RQ Y(!Y'4, M#:HKSRU^%IU91<:G-(UPV20C+M4$Y"LLT[2[8R@ 097(W85.!M8\#)X&1G(Y#PGX3N M-0N+N*.[DB:&7:S+NS(=SC<<..>">2>IY];'Q+\.3:;;0O+[UVU<'' MX>N/#&[4I[V29($=C'(657.TA5RTC#)8C'!YQ@9JEIO@>3Q<@O\ 4I7S+\T4 M<3 *BL!C@A@,C' YP,L2Q. #TFBO.;>&3P->06BR-)9W9V*C_,R-D#(Z #OI43F.UMQ^^>,DE\@ H2. >2NT\<,3N("@ ]!KF+_Q M/+;ZE#I@"^5+$6)(._($AX.<8^0=O6L67X2K9*7L;B6*;!&2W!'7:2@4@$@< M\XQ]TUA^(/#DTFKI;BYFGAA9[10\ MPV[5?A3\PS_$O;)ZBK&GO(\2-, LI12X'0,0-P')X!]S]:X/7-'N?#=A",\$$5R&B:L^I:E=3M(5M MK-=FUG**&&06(!VD?*YRW(!7T&U@=S17FFF:'-X_!OKQVCMF/[F*)A_"2-QR M",CD9(W$Y^ZH +-3TQOAVT5W;RNUJ\@66)R&)+#)8 ;5SM7@\$$#DJ2 >G5 M@>/-4DTJREN86VR)LP< XRZ@\$$=#6_7+?%#_D'3_P#;/_T:E &UX?NFN[:& M9SEWAC9C@#)902<#CK5^O-M'^'9U^W@FOIW8"%/*2/:JHI&0,E3N)&W)P#Q@ ME@ :--@E\$WL-B92]G=;@H<9VMDX4 $X.67+8"MN)(XR #TFBN&\+:C-IU_< M:5<,61LR0F1V8[<\*I?YF^4\\D HW7DU=^).O2:7;". GS[APB;3\_/4J,$D M]%XY!8$'.* .LHJEHMFUE!'#(Q9U10[%F?+8^8[FY()SCT' '%-U[3GU*%K M>*0Q.VW$B9W## GH5/(&.O>@#'^'WB>7Q';M<3!0RRE?D! P%4]R>>:KZEKT MT.K6]@K8ADA+,NU>2!+SG&?X1T/:N)^'WA.XU>W:6&[D@42E=J;L$A5.[AUY MYQT[=:TO$.GSKJEG;0RXF6U5?-==Q^7S0[;6W9) /![GJ.M(#U.BO/K_ .$J MRJ9UN)3=@*1)(V077&#P-P'''S$KQUQ@V/!GC%I-->\N#N:VWJ2[ %RJAE&< M<$[@O^!R0..G)) XSD;]<-\4M/EVP:E -S6NAYIFBBW$G80IV\G R(WX]/F)QU.